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The 16th International Symposium on Laboratory Automation and Robotics provided the largest number of technical
presentations ever offered at this meeting. State-of-the-art development in laboratory automation and robotics were
reflected in the symposium programme which included papers and posters on all aspects of the technology--drug
discovery research, data handling and data management, chemical analysis, bio-analytical applications, managing
laboratory automation, dissolution testing, pharmaceutical analysis, automation and combinatorial chemistry, validat-
ing automated methods and advanced topics. Several new workshops and discussion sessions were included and
activated, and provided even more interactive communication.
Although the programme was very comprehensive, the Symposium was designed to provide time for both formal and
informal exchange of information. The technical presentations were organized into concurrent sessions with grouped
papers on related topics.
Abstracts for each paper (except two that were not available when going to press) and each poster are included here and
the proceedings of the Symposium will be published as a CD-Rom early in 1999. Full presentations of several of these
papers will appear in later editions of this journal.
Integrating drug discovery technologies
ames A. Bristol, Parke-Davis Pharmaceutical Research, Ann
Arbor, MI, USA
The pharmaceutical industry today is entering a new era
wherein a number of new and enabling technologies are
maturing simultaneously. These enabling technologies
include combinatorial chemistry, ultra-high-throughput
screening, genomics, pharamacogenomics, proteomics,
data management, high-throughput methodology for
toxicology, and ADME parameters. In addition, new
and improved automation techniques will have a dra-
matic impact on optimization of these new technologies.
At the same time, the unprecedented productivity and
financial success of new pharmaceutical agents and the
effect of mergers leading to vastly larger single companies
have created unprecedented demands for continued
improvements in productivity that will be translated
directly to increased sales and profits. A further factor
is the increasing trend to outsource key discovery and
development activities to biopharmaceutical companies
and contract research organizations.
These enabling technologies have the potential to trans-
form pharmaceutical discovery into a highly efficient
technological advanced process which will demand ap-
propriate resourcing and integration for optimal effi-
ciency. These developments are the challenges for drug
discovery scientists in the future who, in addition to
having established expertise within their own scientific
disciplines, will necessarily have to work effectively at the
interface of these intersecting technologies and scientific
disciplines.
Coordinated development of multi-site/multi-
functional analytical robotics applications: chal-
lenges and visions
E. F. McNiff, Bristol-Myers Squibb, Princeton, NJ, USA
The analytical development laboratory provides multiple
opportunities for increasing productivity through auto-
mation and robotics. Today’s generation of analytical
scientists has arrived on the job accustomed to using and
developing automated approaches to their work. They
expect automation, and where it does not exist, will seek
to add it. There are many approaches to automation of
an analytical technique. The approach can vary depend-
ing on the scope and impact of the application, but also
whether it is being developed by an analytical scientist or
an engineer. A challenge exists in maintaining the
automation creativity of individual scientists, while pro-
viding a mechanism for an integrated and coordinated
approach to development within a multi-site, multi-
functional organization. From a diverse mix of analytical
chemists, biochemists, process control scientists, software
developers and mechanical engineers, have come a wide
range ofautomated systems. An overview of these systems
will be provided with emphasis on the successes and
challenges of the various development approaches which
were utilized. The ongoing evolution into the current
team approach to automation development will be
presented.
Quality control: organization, cycle times, compli-
ance and efficiency
j. M. Hawkins, Janssen Pharmaceutica, Titusville, NJ, USA
Understanding the contributions that the laboratory can
make in product/process development, process improve-
ment, market surveillance and general business is key to
the pharmaceutical business today. Poor laboratory
practice yields compliance issues, increased cost, in-
creased cycle time and delayed product introductions.
In my presentation, I hope to prompt discussion and gain
agreement and recognition of the laboratory’s contribu-
tion in meeting the expectations of our pharmaceutical
customers. I will cover key areas ofcustomer satisfaction,
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the role of the quality control and quality assurance
laboratories, measures of accountability and progress,
and an example of how our robotics program is helping
Janssen meet our goals.
Automation in the lab: does the tail wag the dog?
Simon Jones, Genetics Institute, Cambridge, MA, USA
Intensive automation of repetitive processes in the lab is
viewed as an attractive panacea for several reasons. First
is the assumption that removal of the human element in
process leads to consistently accurate data sets in a
shorter period of time. Second, and deriving from the
first, is that scientists are ’freed’ to focus their talents on
more creative pursuits. Third, head count can be stabil-
ized and even reduced. Based on this rationale, a virtuous
circle is established that pleases all parties in a biophar-
maceutical endeavour.
However, in reality several issues were overlooked and
unanticipated problems have arisen. First, and the most
serious, is the displacement of the bottleneck in sample
handling to processes up- and downstream of the auto-
mated procedure, e.g. data analysis, compound inventory
and secondary assays in high-throughput screening.
Second, the daily function of automated units requires
repetitive and accurate operation. This frequently leads
to the ’burn out’ phenomenon and turnover of personnel.
Third, a substantial financial investment is required not
only in equipment and bulk materials, but in training
personnel. Fourth, a whole new breed of scientist has
developed to adapt existing bench processes or create
new ones for automated systems.
These issues and their resolution in small molecule drug
discovery will be presented.
The future of high-throughput screening in drug
discovery
John Babiak, Robotics and Automation, Wyeth-Ayerst Research,
Princeton, NJ and Pearl River, NY, USA
High-throughput screening (HTS), in conjunction with
genomics, combinatorial chemistry and molecular mod-
elling, provides pharmaceutical companies with thera-
peutic opportunities never before possible. HTS involves
using automated equipment to test a large number of
samples against a novel molecular or cellular target to
identify a reasonable number of active molecules in a
timely fashion. Under the best of circumstances, the
active molecules identified by HTS can be the chemical
leads which will be optimized into important new
marketed drugs. Because most drug discovery efforts fail
to result in a marketed drug, the primary pressure on
HTS is to do more--more targets and more test
samples--to increase the likelihood of success.
Many HTS groups within pharmaceutical companies
have done more through the use of automation, im-
proved process design and hard work. It is now common
for HTS groups to test several hundred thousand samples
against 20 or more novel targets each year. These levels of
productivity are roughly 10-fold greater than what was
typically achieved just 2 or 3 years ago. The popular
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trends towards assay miniaturization, industrial-strength
automation and new detection technologies further ex-
tend the view that more is better. However, finding more
leads for more novel targets does not necessarily shorten
the time to develop a chemical lead into a drug or
increase the likelihood of success for an individual
project.
In the fiture, therefore, an emphasis needs to be placed
on using HTS resources and expertise to improve the
quality of chemical leads, not simply find more of them.
Concepts in automation, data management and stream-
lined assay design which have been developed within the
HTS environment will be applied to other aspects ofdrug
discovery, e.g. target validation and secondary screening.
Broader adoption of the tools of HTS may be able to
achieve improvements in drug discovery time lines and
cost savings which cannot occur through more and faster
HTS.
Libraries of molecules, screening and optimiza-
tion of hits: a cost-effective approach
Nigel R. A. Beeley, Amylin Pharmaceuticals, San Diego, CA,
USA
As a product-oriented biotechnology company we need
inexpensive solutions for acquiring libraries of molecules,
introducing screening robotics, handling data and auto-
mating chemistry when compared to the larger pharma-
ceutical companies and technology-oriented start-up
companies. We now have access to over 250000 com-
pounds for screening purposes from the following: (i)
pharmacophore-based selective purchasing from several
purveyors of compounds; (ii) risk-sharing arrangements
giving access to relatively large numbers of compounds;
and (iii) participation in a combinatorial chemistry
consortium. We have put in place the necessary infor-
matics and screening robotics to identify hits and analyse
data from the above. In addition, we have re-tooled our
chemistry effort to tbcus on optimization of hits, making
extensive use of parallel synthesis. Some recent examples
from our anti-obesity and anti-diabetic programs will be
presented.
The HTS infrastructure---the right tools for the
task
Mark Beggs, Janssen Research Foundation, Belgium
High-throughput screening (HTS) is a key component of
the pharmaceutical lead identification process atJanssen
Research Foundation. Over recent years, the pharma-
ceutical industry has experienced significant increases in
the throughput capabilities of its HTS functions. In those
companies where HTS has been effectively deployed, it is
now possible to screen the entire corporate compound
collection against a pharmacological target within a
timescale of several weeks to a few months. This cap-
ability has been realized, not as a result of the purchase of
any one particular piece ofhardware, but rather through
the development of a truly effective HTS infrastructure
which matches the needs of the parent organization.
Central to this development is the need to understandAbstracts of papers presented at the 1998 ISLAR
how to effectively combine the use of the different types
of hardware available to the HTS specialist.
The use of both modular workstations and single-arm
robotic systems has underpinned most HTS groups’
operations. Recent advances in the field of multiple-
arm robotic systems and dedicated automation systems
offer even further potential for increasing productivity.
This talk will describe our experience with the use ofsuch
technologies within Janssen Research Foundation’s HTS
group.
Implementation of analytical technologies in a
pharmaceutical development organizationmlook-
ing into the next millennium
Nigel North, Pharmaceutical Technologies, SmithKline Beecham
Pharmaceuticals, Harlow, Essex, UK
Managing the implementation of new technology in a
pharmaceutical development environment has provided
challenges and opportunities to obtain the benefits from
technologies, e.g. laboratory automation. Successful ap-
plication ofnew techniques requires a dedicated resource.
Within our department, this resource was initially a
single person that has since evolved into a team dedicated
to the investigation and development of robotics and
non-invasive analytical techniques, including near-infra-
red. Pharmaceutical development is an important inter-
face between research and commercial manufacturing.
In research, the success of genomics and combinatorial
chemistry will result in a significant increase in the
number of development compounds. This increase com-
bined with the desire of commercial manutZacturing to
move towards parametric release puts an emphasis on the
need for rapid analytical methods. Some ideas on the
techniques that will be required to meet these goals will
be described together with their impact on automation.
Laboratory automation in pharmaceutical devel-
opment: into the new millennium
Stephen Scypinski, Analytical Development, The R. W. Johnson
Pharmaceutical Research Institute, Raritan, NJ, USA
Incredibly, the use oflaboratory automation and robotics
in pharmaceutical analysis and drug development is
almost 20 years old. Those of us who have attended
ISLAR over the past years have heard success stories,
trials and tribulations of automating many types of
pharmaceutical dosage from assays. More recently, the
automation wave has hit the drug discovery area quite
hard, and it is amazing to see the rapid implementation
ofautomation and robotics in areas, e.g. high-throughput
screening and combinatorial chemistry. If one compares
the ’ramps of utilization’ between discovery and devel-
opment in its utilization ofautomation, the question to be
asked is... WHY?
I have asked myself the aforementioned question and
have tried to answer it by factoring in the rigidities we in
development are confronted with, e.g. regulatory
methods, cGMP compliance, method system and com-
puters contributing to the non-usage of robotics in drug
development and pharmaceutical analysis, their contri-
bution is almost certainly small. One must begin to ask
the question: If we in development are indeed gong to
integrate robotics into our repertoire of analytical tools
and techniques, what needs to be done to make this
happen?
Recently joining a new organization helps one establish
perspective and gives a new beginning and new ideas.
One approach being tried is to firmly ’build automation
in’ when designing methods and sample preparation
schemes. This approach accomplishes several things:
(1) shifting the paradigm of conventional sample
preparation to that compatible with automation
(i.e. homogenization);
(2) translating/transferring manual methods to an
automated system becomes more facile;
(3) persons utilizing both see more equivalency be-
tween them, and hence usage is more readily
accepted.
Using several examples, aspects of automation applied to
the challenges we all face as we move into the 21st
century will be highlighted.
Automated analytical equipment for routine test-
ing used in the quality control labs
H. Emmerich, S. Kurschat, W. Seifert, A. Siegle and M.
Fischer, Byk Gulden, Lomberg Chemische Fabrik GmbH, Singen,
Germany
In the past 10 years, laboratory automation (previously
used primarily in clinical-chemical analysis) became a
more important tool for routine testing in pharmaceutical
quality control. The use ofautomated or semi-automated
laboratory equipment can decrease the lab flow-through
time of the samples for release testing of raw materials
and finished products as well as for stability studies, thus
saving manual capacity for other analytical work. There-
fore, to improve elticiency, the first automated equipment
was introduced into the quality control labs of Byk
Gulden in the early 1990s. These instruments were
prototype robotic systems which automated the release
testing of an X-ray contrast medium and stability studies
of enteric coated tablets (including assay and purity
testing). After the implementation and qualification
phase (approx. year for each system), the equipment
has been used over a period of about 4 years for routine
testing and benchmarking studies. The results show that
the lab flow through time for the samples of one contrast
medium batch can be cut in half using the automated
method compared to the corresponding manual pro-
cedure (8 h instead of 16 h). The number of batches that
can be tested per day, week or month is no longer limited
by the working hours of the analysts, but only by the
capacity of the equipment. Due to these positive experi-
ences, a further automated instrument was ordered in
January 1998 for the analysis of a new X-ray contrast
medium produced for the USA market. The first eco-
nomical data for this robotic system show the same
significant drop in the lab flow-through time of the
samples as m.a. tbr the other robotic systems (10 h instead
of 20 h).
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Developing and managing the automated labora-
tory
Muhammad Albrakeh, Iltifat Hasan and Richard Ashley, Barr
Laboratories, Pomona, NY, USA
The development of new laboratory automated methods
is at the forefront of R&D and QC. This technology
enables higher output, reduces waste and promotes safer
laboratory practices, while cutting down operating costs.
Managing such a lab can be both challenging and
rewarding. Barr Labs will discuss first hand the process
of managing the automated laboratory. Topics include
IQ]OQ, preventive maintenance and calibration, necess-
ary training for scientists and systems users, management
suggestions, first-hand experiences, benefits and pitfalls,
and tips which will carry us into the next millenium.
Equipment discussed include: Zymark MultiDose Plus,
Zymark Tablet Processing Workstations (TPW II), Zy-
mark BenchMate II, and Zymark--fully automated--
Batch Dissolution Systems with USP apparatus I & II for
complete on-line dissolution testing, utilizing both UV
and HPLC methods.
Succeeding with bioanalytical automation in a
matrix environment
Glenn A. Smith and R. A. Biddlecombe, Glaxo Wellcome,
Research Triangle Park, NC, USA
The International Division of Bioanalysis and Drug
Metabolism (BioMet) at Glaxo Wellcome is currently
comprised of distinct departments, each serving a specific
role in the drug development process. These departments
are organized into smaller project teams whose members
collectively contain the necessary skill sets required to
advance compounds through their portion of the devel-
opment process and onto the next department. Expertise
in areas, e.g. bioanalysis, HPLFC, LCMS and automa-
tion are no longer centralized but instead are spread
throughout the divisional groups, creating a flat and
balanced organizational structure.
The strengths, weaknesses, opportunities and threats of
such a matrix structure will be cited, and the implications
they have on laboratory automation will be discussed.
Specific examples of successful communication, team-
work and personnel development strategies, as well as
automation technologies and systems that enhance effi-
ciency in a matrix environment, will be shared.
Fully automated SPE-LC-MS-MS: the continuing
story
R. A. Biddlecombe and S. Pleasance, Department ofInternational
Bioanalysis, Glaxo Wellcome, Ware, Hertfordshire, UK
We have previously reported on the application of a fully
automated stand-alone system for SPE in the 96-well
format. Based around a Zymark XP robot, these systems
use a cooled storage carousel, which acts as both a
warehouse for all the labware and a refrigerated storage
unit for the sample extracts, and a custom-built SPE
station. The SPE station incorporates a vacuum mani-
fold, a RAS\RAM station for rapid reagent addition and
a nine- or 12-port solvent switching valve. This station is
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used to perform all the vacuum steps, conditioning,
washing and elution steps. A robotic sample processor is
used to carry out sample loading.
Further developments of the system to allow automated
sample concentration, reconstitution of sample extracts
and protein precipitation in the 96-well format will be
presented.
Working with the manufacturer, we have developed an
on-line system linking the Zymark 96-well SPE system to
a triple quandrapole mass spectrometer. A fully script-
able version ofsample control coupled with the ability to
share files between the Zymark PC and the mass spectro-
meter Macintosh allow a dynamic link to be set up.
Automation of the analysis
human plasma
of Loracarbef in
T. A. Mihalski and A. Witkowski, BAS Analytics, 2701 Kent
Avenue, West Lafaryette, IN, 47906, USA
A recent clinical study required the quantitation of the
antibiotic Loracarbef in human plasma. An HPLC-UV
method for this compound base on manual solid phase
extraction had already been published [Kovach, P. M.,
Lantz, R. J., and Brier, G., J. Chrom., 567 (1991), 129-
139], but it was believed that automation of the pro-
cedure would increase sample throughput. Therefore, a
direct transfer of the manual method to an automated
one was conducted utilizing the RapidTrace
TM SPE
Workstation. The resulting assay was fully validated
and found to be very robust. Use of the RapidTrace
TM
proved to increase both assay precision and sample
throughput.
Comparison ofautomated liquid-liquid extraction
with solid phase extraction using a Zymark Rapid
TraceTM instrument
Thierry D. Mann, Dianne Boland and Michael F. Burke,
Department of Chemistry, University of Arizona, Tucson, Az,
USA
The use of LC/MS in a wide variety of analyses has
caused a rethinking of the need for highly selective
sample preparation techniques in some laboratories. It
is generally accepted that solid phase extraction (SPE)
provides greater potential selectivity than liquid-liquid
extraction; however, the mass spectrum provides a great
deal of selectivity in many cases. If selectivity is not
required, the LLC experiment can be argued to be
simpler and less expensive. Another of the advantages
that solid phase extraction (SPE) has over liquid-liquid
extraction (LLE) has been its amenability to automation.
Recent advances in laboratory automation equipment
though, have made it possible to perform simple liquid-
liquid extractions in parallel. The purpose of this
presentation is to do a direct comparison of SPE and
LLE using automation provided by the RapidTrace
system.
Two formats for performing liquid-liquid extractions
have been investigated. The first utilizes a thin mem-
brane that is transparent to organic solvents. The control
of the flow rate of the solvents employed in the experi-Abstracts of papers presented at the 1998 ISLAR
ment by the RapidTrace allows the issues of solvent
densities, membrane wetting and contact time with the
sample to be addressed. The second format for liquid-
liquid extraction involves the use of a mechanically
supported stationary liquid phase. In this case, a porous
solid support, e.g. diatomaceous earth, is used to support
a thin layer of sample solution. The extracting solvent is
then applied to the cartridge and passes through, while
extracting the analytes. Alternatively, the extracting sol-
vent is used to saturate the surface of the sorbent and the
sample is then loaded onto the column. The analytes of
interest are then eluted using an appropriate solvent. It
should be noted that this approach, like SPE, has effec-
tively two separate extraction steps. The extraction of
acidic, neutral and basic analytes from serum and urine
will be presented with an emphasis on analysis time,
extraction selectivity and other factors that affect recovery.
Experience with a workstation-based multiple
parallel solid phase synthesis system co-devel-
oped by Zymark Corporation and ZENECA Phar-
maceuticals
Richard A. Wildonger and ames B. Campbell, Chemical
Technology Section, Lead Discovery Department, ZENECA
Pharmaceuticals, Wilimington, DE, USA
In response to the rapid advances in the high-throughput
synthesis arena and in consideration of our requirements,
we entered into a collaboration with Zymark Corpora-
tion aimed at co-developing a workstation-based solid
phase multiple parallel synthesis system. Thus, we set out
to automate selected processes associated with multiple
parallel solid phase synthesis, e.g. diversity reagent pre-
paration, synthesis (reagent addition, washing, mixing and
short-term incubation), off-line incubation and product
cleavage. From the start, we held to the tenet that it is the
chemistry that should serve to define the shape of the
automation platform rather than the converse.
We will describe the modules completed to date which
include the diversity reagent preparation station, the
synthesis platform, incubation station and cleavage
station. The synthesis platform is unique in that it
exemplifies three modes of liquid addition, i.e.
plumbed-serial, plumbed-parallel and robot-mediated
plumbed-serial. Furthermore, spent reagents, impurities
and soluble by-products are removed by filtration using
positive pressure differentials rather than vacuum, thus
avoiding atmospheric contamination. Features of the
synthesis platform include:
ninety-six reaction positions (4 x 24 position reac-
tion blocks);
parallel addition of reaction solvents and common
reagents;
robot-mediated delivery of diversity reagents (100);
gentle agitation by intermittent sparge with inert
gas;
heating to 150C or cooling to -75C with an
additional reflux zone for vapour condensation at
reflux;
resin bed washing by parallel means;
quick disconnects for rapid removal of reactor
blocks for remote processing;
all wetted materials are Teflon, PPS, glass or stain-
less steel;
small footprint is accommodated in a standard fume
hood.
A variety of chemistries have been performed to date.
These procedures will be described and compared with
manual methods.
Generation of a directed metalloprotease library
by solid phase synthesis
j. M. Salvino, New Lead Generation Department, Rhone
Poulenc Rorer, Collegeville, PA, USA
Metalloproteases are an important class of enzymes
involved in processing inactive precursor proteins to their
biological active forms. Selective inhibitors of specific
metalloproteases have led to important therapeutic
agents. The design and synthesis of a library of novel,
low molecular weight hydroxamic acids has been under-
taken. This library was constructed on solid phase using a
seven-step sequence, wherein the final hydroxamic acid
formation was performed using a novel in-house devel-
oped linker. Biological testing against numerous metallo-
proteases has revealed potent, selective inhibitors. Details
concerning the scope and limitations of the synthesis,
challenges in automation and biological activity of the
inhibitors will be discussed.
Automated synthesis at AgrEvo
Brian A. Moloney, Automated Synthesis and Combinatorial
Chemistry, AgrEvo UK, Chesterford Park, Saffron Walden,
Essex, UK
This paper will describe the different approaches taken to
automated synthesis at AgrEvo in both England and
Germany. The approach taken in the UK is to have a
series of workstations, centred around a Zymark robotic
platform. Separate evaporation and chromatography
workstations are used to maximize the sample through-
put. In Frankfurt, an ISRA robot with on-line evapora-
tion and chromatography is used to minimize operator
involvement. Each of these approaches will be discussed
in detail in the presentation.
Parallel organic synthesis and combinatorial drug
discovery at Affymax
V. Antonenko, Affymax Research Institute, Santa Clara, CA,
USA
A multi-task consumer products robotics auto-
mation system
Jonathan J. Zieman, Paul L. Morabito, Ramasamy Tamilar-
asan, The Dow Chemical Company, Midland, MI, USA; Paul
D. Hazelwood, The Dow Chemical Company, Sarnia, Ontario,
Canada, and Kevin Wagers, S. C. Johnson Wax, Racine, WI,
USA
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An automation system to prepare and test cleaning
formulations according to large and complex experi-
mental designs was implemented in the former Dow
Brands Business group. Temperature-dependent phase
separation and continuous refractive index measurement
as well as microemulsion room temperature turbidity
may be performed on the prepared formulations, or for
product or competitive analysis. Quaternary amine and
bleach titrations can be performed using a Brinkmann
Titrator integrated into the system. The system will
handle 10 formulation solutions, including relatively
viscous solutions, and prepare and/or test up to 240
samples per run. All formulations are individually speci-
fied allowing maximum flexibility in experimental de-
sign. A Visual BasicTM Graphic User Interface (GUI)
oversees the Zymark System VTM controller, and pro-
vides data input and output with Excel Spreadsheets by
Object Linking and Embedding (OLE). Custom auto-
mation peripherals along with the required EasylabTM
including a SclLog Expert Pump code were produced
TM
to provide one high viscosity solution delivery channel.
Further tests considered were viscosity, conductivity and
competitive analysis for per cent solids. The system has
significant positive economic impact and allows much
more rapid formulation of cleaning products in addition
to reducing the tedium of repetitive manual operations.
Development of a fully automated analysis for the
riboflavin vitamers in unfortified foods
L. F. Russell, L. Brooks and K. McRae, Agriculture & Agri-
Food Canada, Kentville, Nova Scotia, Canada
Demands for more and better nutrient composition data
and the necessity to test large numbers of food samples in
order to generate representative nutrient values is fuelling
the need for laboratory automation. A fully automated
method has been developed for the simultaneous analysis
of riboflavin and its coenzymes, flavin mononucleotide
(FMN) and flavin adenine dinucleotide (FAD) in un-
fortified foods. It combined robotic extraction with
HPLC quantitation. The robotic-HPLC method was
compared with the HPLC quantitation preceded with a
manual extraction. The manual extraction and HPLC
separation have been shown to provide total ribvoflavin
results that are comparable with the standard AOAC
International fluorometric method. The two methods
were compared using foods that are significant dietary
sources of riboflavin, e.g. liver, beef steak, eggs and milk.
The results from the fully automated method compared
favourably with those obtained using manual extraction.
The robotic extraction was faster than its manual
counterpart and permitted determinations to be con-
ducted under conditions that protected the riboflavin
vitamers fi’om degradation and loss during analysis. As
a result, the automated method is suitable for unattended
analysis of the large numbers of samples that are needed
to provide a representative estimate of the mean vitamer
content and its inherent variability in unfortified food
products.
Development and validation of an automated
method for the determination of total fat in food
70
products by acidic hydrolytic extraction and quan-
titative gas chromatography
Lee Pieta and Steven J. Salata, Nabisco, East Hanover, NJ,
USA
In its Nutritional Labeling and Education Act of 1993
(NLEA), the US Food and Drug Administration (USF-
DA) defined total fat as the sum of fatty acids expressed
as triglycerides. Virtually all packaged foods regulated by
the USFDA are required to carry specific nutritional
information on total and saturated fat. The total fat
method adopted by the Association of Official Analytical
Chemist (AOAC) is essentially a combination of two
official methods. A total lipid extract is obtained by first
digesting the sample with an acid. The released fats are
extracted into ethyl and petroleum ethers. Alter gently
evaporating off the ethers, the lipids are saponified and
methylated. The total fatty acid content is determined
using capillary gas chromatography. Nabisco, in partner-
ship with Zymark Corporation, has implemented a
laboratory automation system as the solution to a time-
consuming and technique-oriented procedure.
A method for the determination of amprenavir in
human plasma and serum using a Zymark/Tecan
robotics system and LC,/MS/MS detection in a 96-
well format
Cindy M. Rawls and Glenn A. Smith, International Bioanalysis,
Glaxo Wellcome, Research Triangle Park, NC, USA
A sensitive, robust, high-throughput method for the
determination of amprenavir, an investigational HIV
protease inhibitor, was developed and validated for
bioanalytical support and clinical trials. This protein
precipitation method utilizes an integrated system con-
sisting of a Zymate II robot, a Tecan RSP 8051, a
reagent addition station (RAS) with a 25-port solvent
selection valve for all liquid additions, and a custom
microplate vortex and centrifuge.
Amprenavir and its internal standard (a stable isotope of
amprenavir) are detected on an API-300 triple-quadru-
pole mass spectrometer by atmospheric pressure chemical
ionization tandem mass spectrometry (APCI/MS/MS) in
positive ion multiple reaction monitoring (MRM) mode.
The assay has a dynamic range of 10-5000 ngml-l.
The robotics system processes two 96-well plates in less
than 2 h including sample dilutions. Data presented from
two clinical trials in which more than 3500 samples were
analysed over 20 analytical runs demonstrated excellent
accuracy and precision in both serum and plasma.
Validation test plan for the Packard Multi
PROBETM robotics system
Clark V. Williard, Jason D. Morse and Thomas D. Oglesby,
Taylor Technology, Princeton, NJ, USA
A fully automated 96-well solid phase extraction method
was developed for use in analytical support of GLP
studies. A Packard MultiPROBETM robotics system
was used to automate the preparation and extraction of
standards, QCs and study samples. As part of theAbstracts of papers presented at the 1998 ISLAR
validation scheme for the method and in accordance with
regulated guidelines for computer-controlled systems, a
validation plan was devised and executed. A validation
protocol was created which included a description of the
system, a test plan, reference to related SOPs and
documentation of testing. It addressed requirements of
user verification of the vendor systems and source codes,
change control procedure, application system documen-
tation, and the system’s physical analytical performance
parameters including position control and volumetric
pipetting. The validation plan and results will be pre-
sented. Additionally, the plan will be discussed with
respect to fulfilment of recent regulatory mandates and
guidelines.
Direct injection of plasma for high-throughput
drug metabolism HPLC analysis
Art Sims, Joe Takarewski and Peter Duriga, Cohesive Tech-
nologies, MA, USA
A major time-limiting step in measuring drugs in plasma
is sample preparation. Steps necessary to remove the
drugs of interest fi’om plasma prior to injection into a
HPLC typically require more time than the analysis.
Recent advances in automation of solid phase extraction
(SPE) have greatly reduced the amount ofhands-on time
required for sample clean up, but even automated, this
process is still prohibitive to high sample throughput.
This poster describes new, dynamic flow technology that
allows lbr direct injection of plasma samples and new
levels of sample throughput.
Turbulent flow chromatography, and the resulting con-
vective mass transfer, has removed the time-consuming
sample clean up traditionally required in plasma drug
analysis by allowing direct injection of plasma onto a
specialized column. Relatively large (50 la), phase-coated
particles retain the drugs of interest, while the plasma is
eluted to waste. The drugs can then be quickly eluted
and measured by UV/VIS or mass-specific detectors.
This poster will show data tiom direct plasma injection
and sample analysis cycle times as short as 90 s.
Method optimization approaches using 96-well
SPE disk plates
David J. Ehresman, Greg Lawless and David A. Wells, 3M
Filtration Products, St. Paul, MN, USA
Ninety-six-well solid phase extraction (SPE) in microtitre
plate tbrmat offers a rapid sample preparation approach
lbr the analysis of drugs and metabolites in biological
fluids. Beyond the gains achieved by the microtitre
format and parallel processing of 96 samples, the 3M
Empore disk technology (90% particles: 10% PTFE,
w/w) provides an additional gain in throughput. The
use of disks, instead of traditional packed particle beds,
allows for smaller solvent volumes and the ability to
eliminate the dry-down and reconstitution step prior to
analysis. The conditions under which disks should opti-
mally be used are slightly different than with traditional
products. This presentation will discuss proper usage and
disk plates for maximal efficiency. Also, optimization of
disk-based SPE assays will be discussed with emphasis on
developing a robust, high-throughput assay. In particu-
lar, these aspects ofmethod optimization are discussed in
detail: conditioning solvent volumes, vacuum considera-
tions, sample pretreatment options, sample dilution,
wash solvent strategies to eliminate proteins, elution
solvent optimization and automation considerations.
The 96-well plate format is ideal for examining multiple
parameters within a single plate. A method can literally
be optimized within a single plate, greatly reducing the
time required tbr method development.
Automated liquid/liquid extractions using Varian
Chem ElutTM cartridges and a Zymark XP ro-
botics system
John R. Alianti, Christine M. Grosse and Glenn A. Smith,
International Bioanalysis, Glaxo Wellcome, Research Triangle
Park, NC, USA
Diatomaceous earth (DE) is a silica-based substance
composed of the exoskeletons of fossilized unicellular
algae called diatoms. As the diatoms died, their skeletal
remains blanketed the floors of ancient sea bottoms,
lakebeds and lagoons. Today, DE is excavated, processed
and purified for use in a variety of products including
insecticides and filtration systems.
One important application for DE is in the pharmaceu-
tical industry. Because DE is extremely hydrophilic,
aqueous-based polar drug compounds and their metabo-
lites readily adsorb to this matrix. The compounds can
then be extracted from the matrix using an immiscible
solvent, e.g. ethyl acetate, methylene chloride or chloro-
form
At Glaxo Wellcome, several automated LC/MS/MS and
HPLC bioanalytical assays have been validated using
this procedure because it offers numerous advantages
over conventional solid phase and liquid/liquid extrac-
tions. This poster describes the advantages and disad-
vantages of this technique, the system layout, the
extraction process, automated vial filling and future
trends, e.g. 96-well plate technology.
Automated 96-well SPE-LC/MS/MS for high-
throughput bioanalysis in a contract lab: prob-
lems and solutions
Luca C. Matassa and Patricia E. Paterson, Maxxam Analytics,
Mississauga, Ontario, Canada
Fast bioanalytical analysis techniques, e.g. LC/MS/MS,
require equally fast, or faster, sample preparation tech-
niques to keep pace. Automated 96-well SPE with LC/
MS/MS has been used successfully in our laboratory for 4
years and has provided significant advantages over
manual techniques. There are, however, some specific
problems which must be solved in order to take full
advantage of the technique. Both problems and solutions
of using automated 96-well SPE will be discussed in this
presentation.
Major components include 96-well SPE plate (Waters,
3M, Varian), a robotic liquid handling system (Packard
Multiprobe 104 or 208), and an LC/MS/S and auto-
sampler (PE-Sciex API III-plus and Hitachi 7250).
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Automated 96-well SPE is best applied in high-volume
bioanalytical labs. It eliminates rate-limiting steps of
manual column preparation and liquid transfers by using
96-well plates coupled to robotic handling of samples,
liquids and extracts, thereby providing enhanced
throughput and accuracy. On the downside, the tech-
nique is semi-automated, requiring manual intervention
at some points. Process re-engineering/staff training and
purchase of expensive hardware and consumables is
required. The automation must also be adaptable to
various tubes sizes/configurations and sample matrices
from multiple sources.
Fast on-line Prospekt(R) SPE/HPLC/MS/MS method
for the quantification of methylphenidate in hu-
man plasma (potassium oxalate)
Robert Masse, Christian Lemoyne and Claude Amestoy, Phoenix
International Life Sciences, St-Laurent, Quebec, Canada, Daniel
Carazzato, Bristol-Myers Squibb (Canada), St-Laurent, Que-
bec, Canada, Alain Carrier, Triangle (Canada), Montreal,
Quebec, Canada, and Denis Lessard, Bioanalytical Innovation,
Levis, Quebec, Canada
Methylphenidate is a mild CNS stimulant with effects
similar to that of amphetamine and is frequently pre-
scribed for children with attention-deficit hyperactivity.
A fast automated SPE/HPLC/MS/MS method was de-
veloped to quantify methylphenidate in human plasma
at 0.100ng/ml. Human plasma (100ml) containing
methylphenidate was diluted with water, extracted with
a fully automated on-line solid phase sample clean-up
and injection system (Varian Prospekt
(R) 9200 SPE
system). Separation and quantification were performed
with HPLC/MS/MS. The resultant total run time was
3min. A full validation was completed, linearity was
observed in the range of 0.100-10ng/ml (r > 0.9997).
Observed recoveries for methylphenidate at 0.300 ng/ml,
3.999ng/ml and 7.998ng/ml were 72.0%, 66.8% and
68.7%, respectively. The between-batch CV% for QC
samples at 0.100ng/ml, 0.300ng/1, 3.999ng/ml and
7.998 ng/ml were 7.6%, 5.0%, 4.0% and 3.5%, respect-
ively. Further validation and stability data will be
presented.
Automated analyses of three selected calcium
channel blockers: fetodipine, nifedipine and nisol-
dipine by the Phoenix PhASSETS(R) extraction
robot coupled with gas chromatography
Carl Dourambels, Reng Michaud, ohanne Bouchard, Isabelle
Barbeau, Alain Arseneault and Robert Massg, Phoenix Life
Sciences, Montrgal, Quebec, Canada
The Sample Preparation and Automation (SPA) and
Gas Chromatography (GC) departments at Phoenix
International Life Sciences have jointly developed a set
of unique methods for the analysis of selected calcium
channel blockers (CCBs), i.e. felodipine, nifedipine and
nidoldipine, by gas chromatography either coupled to a
mass-selective detector (MSD) or an electron capture
detector (ECD). The three drugs are structurally similar,
having close chemical and physical properties, and tend
to react in similar ways when exposed to the same
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extraction conditions. Our unique approach in using
automated extraction was PhASSETS (R) (Phoenix
Automated Simple Sample Extraction Treatment
System), an automated extraction system composed of
a liquid pipetting station and a special extraction
cartridge. This system was designed and developed
at Phoenix International Life Sciences. This multi-pur-
pose, automated extraction system has been responsible
for the validation of over 60 analytical methods, using
different means of detection, e.g. HPLC, HPLC]MS,
HPLC/MS/MS, GC, GC/MS and immunochemistry
assays. The PhASSETS (R) extraction system makes use
of the liquid/liquid extraction theory (adsorption/deso-
rption) coupled with a specially treated solid support
cartridge.
The extraction of these drugs from the biological
matrix (human plasma/EDTA) can be accomplished
with a speed of 120 samples in 1.5 h, leaving the analysts
free to perform other duties. Statistical analysis on
between-batch quality control samples led to the follow-
ing results.
Felodipine
QC D QC A QC B QC C
40.44 121.32 3.033 6.066
pg/ml pg/ml pg/ml pg/ml
Mean 43.311 124.485
SD 4.3202 5.9277
% CV 10.0 4.8
Nominal (%) 107.1 102.6
Recovery
(mean) (%) 96.95
N 10 10
3.0743 6.3292
48.6741 172.5209
1.6 2.8
101.4 101.1
9 9
QC D
0.51
ng/ml
Nifedipine
QC A 1.52
pg/ml
Qc Qc c
50.54 70.75
ng/ml ng/ml
Mean
SD
% CV
Nominal (%)
Recovery
(mean) (%)
N
0.455
0.0724
15.9
89.3
6
1.561 52.662 70.621
0.1137 2.1257 2.2034
7.3 4.0 3.1
102.7 104.2 99.8
84.13
6 6 6
Qc D
0.050
ng/ml
Nisoldipine
QC A 0.149 QC B QC c
ng/ml 2.980 5.961
ng/ml ng/ml
Mean
SD
% CV
Nominal (%)
Recovery
(mean) (%)
N
0.494
0.003 12
6.3
98.8
6
124.485 3.1586 6.0734
5.9277 0.149 56 0.185 79
4.8 4.7 3.1
102.6 106.0 101.9
85.23
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Felodipine and nisoldipine were analysed by GC/MSD,
while nifedipine was analysed by GC/ECD. The maxi-
mum run times for these analyses were 6 min per sample.
Analytical batches typically numbered 95 samples. Chro-
matography systems were very stable, and no contamina-
tion or interference at analyte retention times was found
in all blank plasma samples tested. The use of the
PhASSETS (R) extraction system coupled with GC was
found to be ideal for these analyses.
The joint automated analysis of loratadine and
descarboethoxy loratadine (major metabolite) by
Phoenix PhASSETS(R) extraction system and liquid
chromatography coupled to tandem mass spectro-
metry
Reng Michaud, Carl Dourambeis and Robert Massg, Phoenix
International Life Sciences, Montrgal, Quebec, Canada
The Sample Preparation and Automation (SPA) depart-
ment at Phoenix International Life Sciences has devel-
oped a unique method for the joint determination of
loratadine and its major metabolite, descarboethoxy
loratadine, from human plasma by LC/MS/MS at a
quantitation limit of 50pg/ml. PhASSETS (Phoenix
Automated Simple Sample Extraction Treatment
System), an internally developed extraction system has
been used to validate this method and over 60 other
analytical methods for HPLC, HPLC/MS, GC, GC/MS
and immunochemistry departments at Phoenix. This
system makes use of liquid/liquid extraction theory
(adsorption/desorption) on a solid support termed
’thin-film liquid/liquid extraction’. The PhASSETS
robot uses multiple liquid/liquid additions to help selec-
tively improve the recovery of the analyte(s) from the
biological matrix. The following results were obtained.
Loratadine
QC A QC B QC C
ng/ml ng/ml ng/ml QC D
Actual
concentration 0.1506 6.0240 7.5300
Mean 0.14926 5.70400 7.20208
SD 0.010 128 0.235934 0.288902
(%) CV 6.8 4.1 4.0
Nominal (%) 99.1 94.7 95.6
N 21 22 22
9.4
102.2
24
Descarboethoxy loratadine
QC A QC B QC c
ng/ml ng/ml ng/nl QC D
Actual
concentration 0.158 3 6.330 3 7.912 9
Mean 0.16966 6.04556 7.561 63
SD 0.018 167 0.572 729 0.531 295
(%) CV 10.7 9.5 7.0
Nominal (%) 107.2 95.5 95.6
N 21 22 22
0.0528
0.05645
0.006 091
10.8
106.9
22
Recovery of both compounds from (sodium EDTA)
human plasma was 91.5% for loratadine and 84.9% for
descarboethoxy loratadine.
The use of Sciex API-III LC/MS/MS (R), coupled with
Waters Alliance(R) injector, led to 2min run time per
sample, with no contamination or interference at the
drug’s retention times, determined on 10 different blank
plasma samples. The use of a simple mobile phase and
analytical HPLC column also tends to minimize all
variations on the different systems, thus making this a
rugged and robust method for all hands involved in the
process.
Evaluation of 96-well solid phase extraction (SPE)
technology using methotrexate and aminopterin
as drug probes both off-line and using the TOM-
TEC Quadra 96 automated workstation
Carl Dourambeis, Rigas Voyatzis, Trang Nguyen and Robert
Massg, Phoenix International Life Sciences, Montreal, Quebec,
Canada
Ninety-six-well technology has been investigated using
methotrexate and aminopterin as drug and internal
standard (IS) probes, respectively. The flow character-
istics and regeneration of the 96-well extraction blocks
showed differences from manufacturer to manufacturer.
Extraction solvent effects at various levels during drug
extraction showed the dependence of the recovery on the
step in which different solvents were employed. Variable
volumes of sample loaded during the extraction showed
very little dependence on the sample volume used.
Mechanical and chemical weakness in the extraction
manifolds and extraction blocks are discussed. Results
will show a comparison between various vendors’ prod-
ucts as well as optimization techniques leading to the
development of a 96-well method for the isolation and
purification of methotrexate and the internal standard,
aminopterin. HPLC and LC/MS/MS are used as detec-
tion systems. Results of this work are presented.
High-throughput analysis of drugs from biological
matrices with a water-wettable sorbent in a 96-
well extraction plate
Yung-Fong Cheng, Laura Bean, Robert Bonin, Ed Bouvier,
Mark Capparella, Pare Iraneta, Uwe D. Neue, and Dorothy
J. Phillips, Waters Corporation, Milford, MA, USA
Sample preparation is required to maximize the quality
of the analytical results and to minimize the downtime of
expensive, high-overhead analytical tools e.g. LC/MS/
MS systems. Historically, liquid-liquid extraction and
protein precipitation have been the bottleneck in labora-
tory productivity as they are not easy to automate.
Presently, solid-phase extraction (SPE) has been proven
to be more readily automated for high sample through-
put. The most common high-throughput sample pre-
paration is solid-phase extraction in a 96-well format.
The enabling technology for 96-well plates is the single
reversed-phase sorbent that can be used to extract all
drug classes from biological fluids. A genetic sorbent and
a simple SPE method are the keys to automating the
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analyses for pharmacokinetics studies in drug discovery
and the clinical trial samples in drug development.
This paper shows that using the generic OasisTM HLB
sorbent, in a 96-well format, can increase sample pre-
paration productivity. With a simple and well thought
out SPE method development strategy using the poly-
meric OasisTM sorbent, we were able to obtain excellent
results for a wide range ofcompounds. Recoveries greater
than 85% and variability less than 5% were obtained on
OasisTM HLB extraction plates for basic compounds (e.g.
antidepressants and their metabolites) and polar drugs
(e.g. procainamide and ranitidine). More importantly,
because the OasisTM HLB extraction sorbent is universal,
one general method was used for extracting many
different drugs covering a wide polarity range.
High-throughput extraction with a novel poly-
meric solid-phase sorbent for screening drug
candidates
Judy L. Carmody, Pamela Iraneta, Yung-Fong Cheng, Dorothy
Phillips and Uwe Neue, Waters Corporation, Milford, MA,
USA
Rapid and reproducible quantitation of basic and polar
drug compounds from biological matrices has historically
been a challenging, time-consuming endeavour. Necess-
ary sample preparation techniques used to concentrate or
clean up matrices before HPLC of GC analysis have
proven to be either tedious and labour intensive, or
irreproducible. Presently, the most commonly used tech-
nique is reversed-phase solid phase extraction using
porous silica bonded with C18. The major disadvantage
of employing this sorbent with basic compounds, e.g.
doxepin, prevents complete elution of basic compounds
and results in low, variable results.
Highly reproducible and uncomplicated SPE methods
were developed for these types of basic drug compounds
covering a wide polarity range using the novel polymeric
Oasisc> HLB sorbent. Recoveries greater than 90% and
reproducibilities less than 5% RSD were realized even
with using the Oasis HLB sorbent in 96-well plate
format for high throughput. Most importantly, because
Oasis? HLB sorbent is a water-wettable polymer, these
results were achieved without concern as to whether or
not the sorbent ran dry. Straightforward method devel-
opment techniques aimed at offering solutions to prob-
lems associated with the sample preparation of drugs in
biological matrices will be presented.
Integrated biological sample preparation in the 96-
well format
Min Chang, Jack Conrad, Enid Quinn, Matthew Rieser, Tong
Shen, Willium LaBeau, Bahaa Q,asawa and Maury Chu, Abbott
Laboratories, Abbott Park, IL, USA
In order to gain the full benefit of parallel sample
processing in the 96-well format, every step in a sample
preparation scheme must be compatible and preferable
all in the same format. At Abbott Laboratories, inte-
grated sample preparation in the 96-well format was used
to prepare plasma and urine samples. With the exception
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of the initial sample transfer, ordinary steps in sample
preparation, e.g. the addition of internal standard and
sample treatment reagents, mixing, solid phase and
liquid-liquid extraction, evaporation (under nitrogen or
by vacuum), reconstitution, sample clarification (by
centrifuge or filtration) and HPLC injection were all
performed in the 96-well format. Several pieces of small
equipment were designed and custom built in-house to
achieve the best efficiency. Typical sample preparation
times for solid phase extraction were reduced to approxi-
mately 2.5 h per 96 samples from approximately 5.5 h.
Typical sample preparation times for liquid/liquid ex-
traction were reduced to approximately 2.5h per 96
samples from approximately 6 h.
Biological sample preparation by on-line solid
phase extraction
Min Chang, Tong Shen and Maury Chu, Abbott Laboratories,
Abbott Park, IL, USA
Two types of unattended on-line solid phase extraction
procedures were developed. The first procedure uses a
restricted surface reverse phase cartridge to extract the
analytes from the plasma or urine. Proteins and other
interfering components were washed off with an aqueous
mobile phase. After the initial wash, analytes were eluted
into the analytical column by the analytical mobile phase
which was also used for the chromatographic separation.
The extraction cartridge was regenerated alter the
analytes eluted into the analytical column. The same
extraction cartridge was used for the entire analytical
run. The other procedure utilized an OSP-2A (JM
Science) sample preparation unit. Each sample was
extracted onto a separate extraction cartridge (may be
re-used) after activation and conditioning. The extrac-
tion procedure was essentially the same as the previously
described procedure. However, as the sample extraction
and the elution and regeneration of the extraction
cartridge may occur in parallel, extensive cartridge
washing and drying can be performed without increasing
analysis time. A system with four sample preparation
solvents and air drying will be presented. Both pro-
cedures were used to support clinical and toxicity studies.
Operational qualification of a BenchMate tablet
processing workstation (TWP)
John Leedes, Whitehall Robins, Richmond, VA, USA
Recently, Whitehall Robins Healthcare Pharmaceutical
Research and Development obtained a TPW. This work-
station was the first fully automated sample preparation
device brought into our laboratory for routine NDA
product analysis. To satisfy GMP requirements, it was
necessary to develop a qualification and calibration
scheme to ensure that this unit was functioning properly.
A protocol was written and approved which describes the
operational qualification (OQ) testing of the automated
device. The resulting document, described in this poster,
satisfies all GMP requirements and serves as the calibra-
tion method in our metrology program.Abstracts of papers presented at the 1998 ISLAR
Integrating high-throughput
separation science
technology into
Adam M. Fermier, Norberto A. Guzman and Stephen Scypinski,
Analytical Development Department, The R. W. Johnson
Pharmaceutical Research Institute Raritan, NJ, USA
The term ’high-throughput’ has become synonymous
with the streamlining of processes in the laboratory. Up
to now, the application of high-throughput technology
has, for the most part, been restricted to drug discovery.
Indeed, high-throughput screening (HTS) has revolution-
ized the manner in which new molecular entities (NMEs)
are derived from positive assay screens. In the area of
pharmaceutical development, whose mission is to trans-
form an NME candidate into a marketable product, there
is a continual quest for increased productivity, in order to
minimize the total development time between candidate
selection and the filling of the appropriate regulatory
documentation to apply for product registration.
With this mindset, the analytical laboratory is expected
not only to analyse an increased number of samples with
a high degree of accuracy and precision, but is also
expected to develop and validate methodology, conduct
physiochemical characterization studies, etc. in a time-
constrained fashion. Pharmaceutical analysts rely heavily
upon separation science to conduct their daily activities;
however, separations are by definition one of the slowest
of analytical techniques. In our laboratory, we have
begun to apply the concepts of high-throughput tech-
nology to chemical separations. In this regard, we have
constructed an instrument capable of parallel processing
up to eight simultaneous samples utilizing capillary array
technology.
The reasons for our choice of capillary technology were
several. First, a capillary array instrument would be
capable of performing both chromatographic and elec-
trophoretic separations, thereby rendering it more versa-
tile. Secondly, capillary separations are faster and do not
utilize large volumes of reagents or sample. Finally, they
conserve space. The capillary array instrument described
here consists of eight columns running in parallel. Detec-
tion is accomplished by monitoring the absorbance of the
eight channels simultaneously with a fibre optic system.
The system is controlled via a personal computer inter-
face. The design, testing and demonstrated usage of the
system will be presented in this poster.
Development and validation of an automated
method for dissolution testing of a multi-com-
ponent antiviral drug using the Zymark Multi-
Dose Workstation
Toni M. Terry, Glaxo Wellcome, Research Triangle Park NC,
USA
The Zymark MultiDose Dissolution Workstation has
been used as a standard platform tbr automated dissolu-
tion testing with USP Apparatus II conditions for solid
dosage forms of pharmaceutical products. Early versions
of the MultiDose system allowed for both off-line and on-
line testing by chromatographic and spectroscopic meas-
urement methods. Subsequent nanipulation of the data
had to be performed manually or using spreadsheets.
This approach could prove especially tedious for multi-
component products. The latest version (2.1) employs the
MultiLink Excel-based software for data quantitation.
Additionally, version 2.1 has an interface with the
Hewlett-Packard (HP) 8453 UV Spectrometer. The
HP software contains programs for manipulating data
from single and multiple measurements. This poster will
discuss the process by which a multi-component analysis
(MCA) method is developed and validated using the
MultiDose 2.1-HP8453-HP ChemStation UV software
platform. A detailed description of the hardware and
software configuration is presented, along with analytical
validation results for the product tested.
A vision-based system for automatic determina-
tion of antibiotic content
Margarida Machado, De_partamento de Electrdnica, INETI,
Azinhaga dos Lameiros, Estrada do Pa,co do Lumiar, 1699
Lisboa Codex, Portugal
Antibiotic content determination is essential not only for
controlling the quality of pharmaceutical and other
products in which the antibiotics are used as additives,
but also to ensure compliance with legislation. The
microbiological method for evaluation of antibiotic con-
tents is based on the observation of specific microorgan-
isms’ reaction to these chemical substances. This reaction
takes the form of inhibition halos that appear in the
culture medium, around circular cavities where the
antibiotic was introduced. As the halos’ diameters are
directly proportional to the antibiotic concentration, it is
possible to evaluate sample contents by comparing their
responses with those from standards with known activity.
Traditionally, the reading of the halos’ diameters is
performed manually by human operators with the help
of a digital calliper. These readings involve repetitive
manipulations which, besides being time consuming and
tedious, demand great precision.
The vision system presented evaluates antibiotic content
from images of Petri dishes with inoculated culture and
eight inhibition halos, corresponding to four different
dilutions of the standard and the sample.
The automatic determination method has four phases. In
the first one, an initial segmentation is performed trying
to obtain the halo’s contours. This segmentation is
executed taking into account global information ob-
tained from the histogram. Then a validation analysis is
carried out in order to identify the halos and eliminate
error situations, like, e.g. the consideration of a halo’s
hole instead of the halo itself. In this analysis, factors, e.g.
the object’s circularity, area and centre position are
considered. Situations of non-detection are also analysed.
After this second phase, a third one is triggered in case of
possible errors detected. It consists of a second segmenta-
tion, performed in restricted areas and using local intensity
information, followed by another error analysis. For the
halos identified, a diameter determination procedure is
executed. This procedure tries to minimize the fact that
halos are not ’perfect’ circles, by averaging the distances
between opposite contour points situated at equally spaced
angular intervals. Finally the content is evaluated using
the diameter’s values according to the standard norm.
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Besides the automatic capability, the system also offers
the possibility of diameter’s correction, either automatic,
semi-automatic or manual, so that the user can observe
the effects ofcontent value. An automatic transfer ofdata
to a worksheet is also available.
The tests performed on two antibiotics, Zinc Bacitracin
and Tylosin, for three different content values showed a
mean difference inferior to 2.5% of the expected theor-
etical value, between content values obtained from
manually determined diameter values and those given
by the system in automatic mode without corrections. A
standard deviation inferior to 2.5% was observed. The
values with automatic correction are of the same order.
A robotic system for skin permeation test in
pharmaceutical research development
P. Marty, C. Faure and F. Laroche, Institut de Recherche Pierre
Fabre, Rue Jean Rostand, 31319 Labege Innopole, Cedex, France
In vitro skin permeation tests using static diffusion cells are
commonly used in pharmaceutical development to assess
the delivery of dermal or transdermal dosage forms
through biological (skin) or artificial membranes. Among
the various models described, the Franz cells model is
currently still the reference even though it was initially
designed for manual sampling (using a syringe), at
different time intervals, of the receptor medium. For this
type of implementation, a robotic system has been
developed to automate sampling for U5 Franz cells
arranged on three thermostatically controlled trays.
The advantage of this system is that it provides increased
capacity, productivity and reproducibility of the basic
permeation test, while still using the standard cell model.
Improved reproducibility is obtained through better
temperature regulation, better control of the displaced
volumes (sampled quantities and replaced volumes) and,
more generally, by creating uniform manual operations
for the methods currently being performed.
Validation of an automated waste shot work-
station--determination of weight of actuation
Mark . Richards and Robin V. Platt, Rhdne-Poulenc Rorer,
Holmes Chapel, Cheshire, UK
The process of validating methods for use on an auto-
mated workstation (MDI FD-10 Station, InnovaSys-
tems, Pennsauken, NJ, USA) for the handling of waste
shots fiom metred dose inhalation products is best
managed when broken into various tasks (i.e. shot weight
equivalency, medication delivery equivalency). This pos-
ter will present the activities related to determination of
average weight of actuation (as per cent of target
weight); comparing shot weights of manually actuated
MDI canisters with canisters actuated on two different
MDI FD-10 Stations. Shot weight data are presented as
a per cent of target shot weight.
Using two MDI FD-10 Stations, 60 canisters, containing
200 puffs each, were actuated. Weights were recorded
prior to placement in the MDI FD-10 and at every 10
actuations hence. Manual shot weights were collected
using three analysts actuating 30 MDI canisters contain-
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ing 200 puffs each. Each analyst actuated l0 canisters
each and recorded shot weights prior to actuation and
every 10 actuations hence.
Using statistical tests, the data collected show that the
MDI FD-10 Stations are statistically equivalent with
manual actuation and weighing of MDI canisters. A
summary of the data is shown in the table.
Means of actuation
MDI MDI
Manual FD- 10#1 FD-10#2
Mean shot weight (% of target) 97.5 97.9 98.3
SD 3.352 1.451 1.307
CV 3.4 1.5 1.3
n 598 600 599
Min. shot weight (% of target) 80 90.9 95.4
Max. shot weight (% of target 109 104 103
The results of automated actuation of MDI canisters
using the MDI FD-10 Station reflect lower coefficient
of variances (CV) and standard deviations (SD) when
compared with manual actuation. In addition to the
statistical equivalence of the results, the tremendous
reduction in risk of repetitive strain injuries when using
the MDI FD-10 Station when compared to manual
actuation of MDI canisters is important. Not only will
the MDI FD-10 Station significantly reduce the user’s
exposure to repetitive strain injury-related activity, but it
will also provide the analyst’s need to shake and fire
multiple MDI canisters needed for testing.
Automated sample preparation of Roxifiban
tablets: transfer of a manual method to a robotic
workstation
William Shamrock and David K. Lloyd, Pharmaceutical R&D,
The DuPont Merck Pharmaceutical Co., Experimental Station,
Wilmington, DE, USA
Automation offers obvious advantages for the prepara-
tion of tablets prior to analysis by HPLC, including
unattended operation, minimization of human interven-
tion and an electronic audit trail. However, significant
effort has to be put in up front to develop and validate an
automated method, particularly if it is required to closely
follow an existing manual method. Here, method transfer
for Roxifiban, a fibrinogen receptor antagonist, will be
discussed. A Zymark Tablet Processing Workstation II
(TPWII) was used for all robotic sample preparations.
Manual methods for composite assay and degradation
products testing of a tablet formulation were transferred
to the TPWII. The method involved dissolving the
dosage form by homogenization, filtration of the homo-
genate, dilution of the filtrate and transfer to autosampler
vials. Obstacles to a quick transfer included limitations in
the volume capabilities of the TPWII, poorly soluble
analytes, and proper conditioning of the transfer lines
and filter. After resolving these issues, a validated method
was achieved. Spiked recoveries were from 99.4% to
101.1% (RSDs <0.5%). A cross-validation between
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by Westlake analysis giving a 0.7% calculated interval of
the 95% confidence level. Carry-over was 0.07% after 20
sample preparations at the highest tablet strength.
Automation of Andersen impaction testing of
pressurized metered dose inhalers
Jonathan Faulkes, Rob Whyard and Astra Chamwood, Lough-
borough, UK; Malcolm Smith, Novi Systems, Maidstone, UK
The Anderson impactor is an established device for
characterizing the size distribution of particles in an air
flow. This manual apparatus has become the standard
technique for determining the particle size distribution of
the delivered dose from pharmaceutical inhalation prod-
ucts. As a manual method it is time consuming, resource
intensive and repetitive. Automating Andersen testing
has been a high priority within the pharmaceutical
industry.
A collaborative project between Astra Charnwood and
the automation company Novi Systems has led to the
successful automation of Andersen testing. This was a
very difficult automation project due to the design of the
manual device. To aid acceptance by regulatory auth-
orities, the internal construction of the Andersen im-
pactor could not be significantly altered.
The philosophy of the automated system is discussed
along with the operation and parameters that may be
altered to develop an automated test method. Validation
data are also presented showing the equivalence between
auto and manual determinations. The potential resource
savings and reduction on the variability of results from
going from a manual to an automated system are also
discussed.
Dissolution bath sampling and analysis optimiza-
tion
Charles R. Frey, Gilson, Middleton, WI, USA
Dissolution testing guidelines require precise and accu-
rate control of temperature, stirring configuration and
sampling time. Due to the extended length of tests and
sampling time requirements, sampling and analysis pro-
cedures are typically automated. Depending on the level
of automation that can be achieved, actual sampling and
analysis procedures may be less than ideal with signifi-
cant sampling time variations and analysis inconsisten-
cies.
Optimization of sampling and analysis procedures can
significantly improve dissolution test performance. Bath
sampling can be performed serially (one bath at a time)
or in parallel (all baths simultaneously) with the latter
being the preferred option. Analysis is typically per-
formed in a serial manner using either a direct sample
analysis or a chromatographic separation for specific
analyte detection. If multiple analytes are involved,
multiple separations may be required. In addition to
sampling and analysis optimization, integration of these
processes into a single optimized sampling/analysis plat-
form offers the advantage of accurate and reproducible
control of all sampling and analysis operations without
analyst interaction and the associated potential for error.
This poster will present current technology that can be
applied to optimize automated dissolution testing. Op-
tions range from parallel bath sampling with multiple
sampling probes and multiple flow injection valves for
direct sample analysis to serial sampling with a single
probe and multiple flow injection valves for automated
analysis with multiple HPLC systems from a common
sampling and analysis platform. The control options
required to achieve these levels of automation will be
presented.
An open BenchMateTM system for the analysis of
cleaning validation samples
P. Deuringer and R. SchO’nneis, Bayer AG, Business Group
Pharma, Quality Assurance, D-51368 Leverkusen, Germany
Cleaning validations are necessary to verify that the
pharmaceutical processing equipment is free of contam-
ination from both active substances and cleaning agent
after its use. The cleaning validation procedures for
complex equipment results in a multitude of samples.
The BenchMateTM system of Zymark
(R) Corporation was
found to be a suitable unit to analyse the large sample
load.
In the QA laboratories, the swab samples which were
taken from the equipment are directly transferred to the
Zymark
(R) BenchMateTM test tubes.
Some problems were encountered when using an ’off the
shelf’ TM commercially available BenchMate
the cannula hit the swab sample in the tube while
filling the sample tubes with solvent, so that the
balance was influenced;
the cannula became clogged with swap materials;
sample solution was lost because the dipping speed
of the cannula is very fast.
Therefore, the critical filling and sampling procedures
were reprogrammed using the open-mode operation.
Additionally, the time-consuming manual input for mul-
tiple methods and the data transfer were optimized by
connecting a PC. An Easyfill
TM station was added to
back-up samples.
Automating a ’simple’ moisture method
Steven J. Salata, Nabisco, R&D, East Hanover, NJ, USA
Nabisco’s earliest venture into robotic laboratory auto-
mation started in 1986. The test chosen was moisture by
vacuum oven weight loss, one of the most common in the
food industry. It was considered ’simple’ in the hands of
any technicians, so improved productivity and precision
was the goal. That system was developed, refined and
used routinely over the course of the next 5 years.
Constant tweaking and tuning by the chemist who was
the ’owner’ of the system allowed it to operate reliably
enough to justify its space and maintenance cost, but
disappointingly, it was not as ’good’ as an experienced
technician, even if its repertoire was limited to sample
types that were homogeneous, easily pourable powders.
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As our laboratory staff turned over, new users had no
original developers around to coach them. Inconsisten-
cies appeared in routine validation check samples with-
out obvious cause. Increased concern with GLP and
achieving higher productivity with fewer hands provided
reason anew to redesign the system. This poster illustrates
how that implementation led to identifying subtle but
critical non-robotic factors and an unanticipated extra
phase of the project to assure data quality.
A robotic system designed for multiple applica-
tions
Danh Nguygen and Martin Phillippi, The Clorox Company,
Technical Center, Pleasanton, CA, USA
Due to the relative high cost of robotics compared with
other laboratory equipment and the high impetus in
industry to regulate staff costs while increasing produc-
tivity, we have worked toward developing a robotic
system capable of readily performing multiple applica-
tions. Although it is not unreasonable to utilize PyTech-
nology capability for interchanging stations or other
table modifications, we have found that the per cent
utilization drops dramatically when anything but minor
set-up changes are required between applications. In
addition, changing certain stations may present safety
concerns due to their weight, size and table location
presenting a whole new set of issues. Component switch-
ing between applications may also be a potential source
of error if it is overlooked by the end user.
At our Research and Development Center, there is no
single, redundant application that would justify the
purchase of a robotic system if the criteria were that
the purchase price be recouped in 1-2 years of service. In
addition, changing and evolving product lines and
project priorities cannot ensure the long-term utilization
of an automated system based only on a single applica-
tion. The table layout and programming of our Zymark
XP robotic system were designed in such a way that
multiple applications can be easily implemented on it by
the end-user with minimal training. The types of appli-
cations,table modifications/adapters utilized, and periph-
eral equipment which enhance the system’s versatility
and multiple application capabilities will be discussed.
Extraction and derivatization of acid and neutral
impurities in illicit heroin using the XP robotics
system
Sam D. Cooper, Drug Enforcement Administration, Special
Testing and Research Laboratory, McLean, VA, USA
The instrumental phase being used in this laboratory for
identifying acidic and neutral impurities in heroin
samples requires approximately 60 min for an acceptable
separation of all components. The manual method for
extraction and derivatization of components required
approximately 30min. However, due to the instability
of the derivatized components, this manual method, even
with an autosampler, did not provide a workable solution
to the problem of increasing productivity.
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The XP robotics system enables the analyst to continu-
ously prepare samples and proceed directly to the instru-
mental phase of the analysis.
In this presentation, the XP robotics system will be
described with examples of programming which coordi-
nates the extraction and derivatization procedures with
the analytical processes. Photographs of different stages
of the extraction procedures will be presented with
accompanying descriptions of the advantages of this
protocol.
Automation of residue analytical methods for
determination of pesticides in soil
Herbert Sommer, Volker Koch and Markus Schuld, Bayer AG,
Agriculture Center Monheim, FRG
A new residue analytical method for determination of a
new plant protection compound and its metabolites in
soil has been developed. Different analytical techniques
were used to improve precision, repeatability and repro-
ducibility of methods for the determination of pesticides
in soil and to reduce costs. For this, the most time-
consuming steps have been automated or eliminated.
Three main modules are used:
ASE 200 extractor
Zymate XP robotic system
API 365 or Quattro II--HPLCmMS/MS system
After extraction of soil samples with an ASE 200 ex-
tractor, the crude extracts are transferred to a Zymate
XP laboratory robotics system that performs evapora-
tion, reconstitution, centrifugation and filling into HPLC
vials. If necessary, sample preparation is completed by a
solid phase extraction station on the robotic system.
Because of the high selectivity of HPLC-MS/MS, clean
up is not currently used. The active ingredient and three
metabolites are ionized using an electrospray interface.
For quantification of the analytes, internal standards are
added post-column utilizing a second injection port to
compensate possible matrix effects in the ion source.
Comparison of commonly used robots for labora-
tory automation
Rodney Stockton, SLR Systems, Vancouver, WA, USA
The most commonly used commercial robots utilized in
laboratory automation systems will be presented. Im-
portant parameters, e.g. speed, reach, payload, commu-
nication and software descriptions will be compared
between the various models. The presentation will in-
clude a purely physical description as well as more
subjective comparisons based upon the author’s experi-
ence.
Robots to be included (but certainly not limited to) in
this comparison are manufactured by Beckman, Cavro,
CRS Robotics, Fanuc, Hamilton, Hudson Robotics,
Mitsubishi, Motoman, Panasonic, Seiko and Zymark.
When multiple models from one manufacturer are avail-
able, all models normally utilized in laboratory opera-
tions will be covered.Abstracts of papers presented at the 1998 ISLAR
Formulation tools for cosmetic and personal care
laboratories
Stephen D. Phelan, Formation Systems, Westborough, MA,
USA
Over the past decade, there have been striking advances
in computer hardware and software. Surprisingly little of
this technology has trickled down to the R&D labora-
tories of household product manufacturers, which are
distinguished by a much greater degree of variability
than laced by discrete manulacturers. Recently, however,
tools for both R&D and production chemists in process
companies have become available. These tools address
formula development and management across the en-
terprise, helping companies not only to improve the
productivity of their chemists but also to achieve faster
time to market. Such tools encompass marketing claims
and specifications management; laboratory tests,
methods and results; formula creation; guidelines and
restrictions; formula approvals and distribution; produc-
tion support; and manufacturing feedback. Use of these
tools can drastically increase the value of the formula
base, which is the primary intellectual property of the
consumer goods manufacturer.
Reaction screening and optimization by auto-
mated workstation-based systems: Part I
L. C. Hsu, E. Webb and L. Pin, SmithKline Beecham
Pharmaceuticals, King of Prussia, PA, USA
The shortening ofdrug development timelines has caused
Chemical Development to rethink its strategies for prod-
uct development. One approach has been to incorporate
robotics and automation into new drug development
paradigms. This paper will discuss the hardware and
the custom chromatographic configuration required for
screening and optimization of the Suzuki coupling reac-
tion. The reactions were performed in a STEM block and
the samples were transferred to a Zymark BenchMate
workstation for further sample preparation, including
dilution and filtration. The treated samples were then
analysed by an HPLC system that was directly connected
to the BenchMate workstation. Finally the chromato-
graphic system was configured so that data can be shared
between Synthetic Chemistry and Environmental Re-
search Laboratory via SmithKline Beecham network.
This automated approach has the potential for accelerat-
ing drug development and process optimization in
Chemical Development. The modification ofBenchMate
and the intranet data infrastructure will be discussed in
Part II of the series.
A custom Zymate system for printing and apply-
ing bareode labels
Brent T. Butler and Joan Frezza, Department of Molecular
Biochemistry, Glaxo Wellcome, Research Triangle Park, NC,
USA; Joseph D. Simpkins and Anne Shrago, Department of
Research Technologies, GlaxoWellcome, Research Triangle
Park, NC, USA
We have developed an automated plate labeller for
labelling both 96- and 384-well assay target plates. This
PyTechnology system employs a Zymate II robot with a
Zymark storage carousel and a print and apply labeller.
The labeller has been modified to house a barcode reader
for plate verification. It takes about min to get a plate,
print and apply a barcode, and return the plate. The
label contains both barcode and human-readable inlbr-
mation. The labelled target plates are subsequently
loaded on a compound handling robot [Frezza, J.,
Tomlinson, J. j., Klemp, M. and Butler, B. T., Fully
automated compound distribution to multiple biochem-
ical targets. International Symposium on Laboratory Automation
and Robotics, Boston, MA, October 1997] for processing.
The system is controlled through a Visual Basic front end
that retrieves barcode information from an ORACLE
database. The barcode information is downloaded to an
ASCII text file as a feature of the database software. A
Visual Basic interface processes this information and
transfers the appropriate data to EasyLab variables for
use by the barcode labeller.
The new era in high-throughput screening: minia-
turized assays with 1536 Wells
Giinther Knebel, Greiner GmbH, Frickenhausen, Germany
The necessity of miniaturized low-volume assay plates is
mainly driven by limited availability of test material,
savings in reagents, higher throughput and finally, less
cost per well. Today, 96-well and 384-well plates are in
use, but significant developments must evolve to meet
further requirements to reduce cost per assay. This
constraint leads directly toward even higher density
plates.
In close cooperation, Bayer (Germany) and Greiner
developed a new high-density plate on a non-proprietary
basis that fulfills the requirements in fully automated
systems. To utilize space most efficiently, the only focus
was 1536 wells, a four-fold increase over a 384-well plate.
The centre of a group of 16 wells is still unchanged at
9.0 mm, while the well-to-well pitch is 2.25 mm. A well
volume of 12 gl allows bioassays and cell-based assays to
be carried out. A new optimized well geometry in a
square-rounded shape has been nade to overcome wick-
ing in the corners.
Furthermore, there has been strong evidence that clear
bottom plates will be required. A new moulding and
process technology enables us to manufacture unique
clear bottom plates with ultra-thin films (751am). The
film bottom offers excellent optical properties, reduces
light tunnelling and minimizes well-to-well crosstalk.
White opaque and black clear bottom microplates are
advantageous when microscopic monitoring is required
(e.g. cell-based assays). These clear bottom plates will
have a major impact on assay application and new
instrumentation for the detection of luminescence or
fluorescence assays.
This talk will cover the application of solid and clear
bottom plates in automated assays. Also, we will report
on how liquid handling and imaging can be combined,
and ongoing developments for updated 1536-well ver-
sions.
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Intranet control over several liquid handling work
cells via active XTM
Jeffrey A. Guss, Bristol-Myers Squibb, Wallingford, CT, USA
In an effort to streamline deployment and maintenance
of liquid handling applications over several work cells, a
novel approach using Active XTM was used to program a
user interface coupled to vender-specific software. The
benefits of undertaking this project are that it provides
single-point application development, increased security
and a thin operating environment. In addition, the
application can be run ’off-line’ from the work cells. This
capability allows programming and debugging from
remote locations. The Active XTM Intranet application
contains an Access 97 database, interface tools for the
liquid handling work cells, Hamilton Eclipse 4.1 soft-
ware, liquid handling method selection, and a link to a
paging system. The combination of the Active XTM
Intranet application components and the consolidation
ofdeployment to a distinct location makes tracking work
cell activity and any errors a more manageable task.
Fluorescence-based assays in microwell plate for-
mat for high-throughput drug screening
Steven F. Gessert, Suzanne W. Jones, A. Lee Lang, Toddy
Sewell and Sydney B. Shaw, Chromagen, San Diego, CA, USA
Rapid advances in the generation of potential drug
targets through genomics and concurrent strides in the
creation ofdrug candidates through combinatorial chem-
istry have dramatically increased the demand for sensi-
tive, rapid, automatable drug screening assay formats.
Chromagen has developed fluorescence-based gene
transcription and protease assays in a high-throughput-
compatible microwell plate format. These assays
incorporate three of Chromagen’s proprietary core
technologies:
(1)
(2)
novel fluorophores and fluorogenic enzyme sub-
strates specifically developed for simultaneous
multianalyte detection;
microwell-based, solid-phase extraction chemis-
tries for the isolation and purification of nucleic
acids and peptides; and
a scanning photon-counting spectrofluorometer
capable of providing simultaneous multi-target
detection.
The gene transcription assays [developed for the human
cytokines tumour necrosis factor-alpha (TNF- and
interleukin-6 (IL-6)] utilize DNA probes designed to
recognize specific sequences in target mRNA, and re-
quire neither nucleotide amplification nor reporter gene
constructs. Detection levels in the attomole range (10E-
8 mole) of specific mRNA are routinely achieved using
lysates from 10E5 cells per assay well. The mRNA assay
platform is applicable to numerous genes and can be
optimized for cell lines for a variety of organisms. The
protease assays developed for the coagulation cascade are
homogenous assays and measure kinetics of substrate
metabolism.
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POLARA: a versatile architecture for scheduling
and running microplate assays
Daniel Sipes, Joyce Kuoha and Jonathan Rosen, Ligand
Pharmaceuticals, San Diego, CA, USA
POLARA (Programming Architecture for Laboratory
Automation) is a Windows NT-based software package
for laboratory automation produced by CRS Robotics
(Burlington, Ontario, Canada). An overview of the
installation and operation of POLARA on an existing
custom CRS Robotics system for cell-based assays in
microplates will be presented.
NMR and automated reaction monitoring
M. Armitage, J. Richards, K. Sutcliffe and S. Moore, Smith-
Kline Beecham Pharmaceuticals, Tonbridge, Kent, UK
Chemical Development within SmithKline Beecham is
charged with developing an efficient process for the
manufacture of drug substance. Such a process must
be demonstrated to be safe, robust, economically viable
and environment friendly at a manufacturing scale. A
thorough understanding of the chemistry using reaction
monitoring can help achieve these goals.
Monitoring has traditionally been performed off-line
using techniques, e.g. TLC or HPLC, but NMR poten-
tially gives much more information about the pathway of
a given reaction. An on-line NMR reaction monitoring
system therefore would be beneficial to the scale-up
process. Whilst proprietary systems specifically designed
to perform these tasks are becoming available, we tried to
implement such a system with what was available to us.
This poster describes our experience with a reaction
monitoring set-up using an NMR spectrometer fitted
with an LC-NMR probe and a Gilson 231 autosampler.
The Gilson 231 autosampler consists of an XYZ robotic
arm and a diluter unit. The instrument is programmable
and capable of sampling, dilution and injection of
aliquots of sample, and should therefore provide a suit-
able system for introduction of a sample into the NMR
spectrometer. Our goal was to automate the system as far
as possible such that unattended operation could be
achieved.
Automated liquid handling confirmation of a
Tecan Genesis
Jimmy Bruner, Rusty Czerwinski and James Ormand, Glaxo
Welcome, Research Triangle Park, NC, USA
An application has been developed to perform auto-
mated gravimetric confirmation of the Tecan Genesis’s
liquid handling system. The application was developed in
response to the time-consuming manual liquid handling
confirmation required for Good Laboratory Practice
(GLP) compliance. The system consists of a Tecan
Genesis 100, a Sartorius RC250S analytical balance,
and a custom ActiveX DLL for communicating with
Tecan Logic version 2.11. The system components were
integrated using Microsoft Excel 97.
First, an ActiveX DLL was created to allow communica-
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version 2.11. The LogicPipeComm.DLL consist of two
components, connection and communications. The con-
nection component was created in Microsoft Visual
C+ + and connects to the Logic pipe. The communica-
tions component was created in Microsoft Visual Basic
version 5.0 to access the connection component for a pipe
handle, and to write data to and from the Logic pipe.
Second, an Excel 97 VBA (Visual Basic application) was
created. The Excel application integrates the LogicPipe-
Comm.DLL, Sartorius RC250S analytical balance, and
Tecan Logic version 2.11. The application controls all
balance operations, starts the Tecan calibration method,
receives data from the balance, and calculates the mean,
standard deviation and per cent bias of replicate aliquots.
The LogicPipeComm.DLL gives us the capability to
control Tecan Logic via external programming plat-
forms, e.g. Visual Basic and Excel. Integration of the
Tecan and a balance reduces the time the scientist must
spend recording weight data needed for GLP compli-
ance.
Versatile object weighing on a Zymark BenchMate
,immy Bruner, David Igo and Sonia Shamdasani, Glaxo Well-
come, Research Triangle Park, NC, USA
An application has been developed to perform fully
automated weighing of various objects on the Zymark
BenchMate. The application, known as ’ZyWeighing’,
was developed in response to the time-consuming manual
method of weighing containers and contents used in
chemical investigations. The ZyWeighing system consists
of a standard Zymark BenchMate, Zymark EasyServ
OLE Server, custom object carriers, and custom pro-
grams.
The software consists of three elements. First, a Visual
Basic program was developed using OLE technology to
access the EasyServ OLE and Microsoft Excel. Second,
an Excel workbook was created for capturing the experi-
ment and weight data. Finally, EasyLab programs were
created for running on the BenchMate Controller.
Customer carries were developed for objects of various
size. Each carrier was designed to fit the standard
BenchMate rack.
The system has been shown to reduce the amount of time
a scientist spends performing weighing operations for 4 h
to 30 min for a standard set of 100 samples. Precision was
assessed by weighing 50 individual samples 100 times
using the resident Sartorius Model XH110 balance. The
standard deviation was less than or equal to 0.1 mg.
Accuracy was examined using standards having masses
ranging from 5mg to 2g. The weights ranged from
100.00 to 101.00% of their theoretical values.
Ultra-high-throughput data analysis
Neil Carlson, Nick Ware and Michelle Palmer, Assay Develop-
ment Services, Tropix, Bedford, MA, USA
Now that it is possible to run 100000 assays in a 24-h
period, it is critical to look beyond the physical issues of
running these assays, and to address the impact of ultra-
high-throughput screening (UHTS) on post-assay data
processing. Data collection, storage, back-up and protec-
tion are only a small part of the overall problem. The
more challenging task involves presenting this large
volume of data in such a way as to allow scientists to
make correct, timely decisions about potential errors in
plate processing or treatment during the assay; to mark
specific compounds, rows or entire plates for retesting in a
particular assay; to quickly find statistically significant
’hits’; and to assign a compound for further testing in
subsequent assays. This poster presents one approach at
addressing these issues, and explores future possibilities
with regards to data presentation and ’pre-analysis’ of the
data generated during UHTS.
Strategies for high-throughput HPLG purification
for combinatorial chemistry
j. Carmody, U. Neue, R. Crowley and C. Andres, Waters
Corporation, Milford, MA, USA
Traditionally, the search for biologically active molecules
has involved the synthesis of one-molecule-at-a-time
discovery strategies. This has proven to be a very time-
consuming and labour-intensive process for the discovery
ofnew drugs, catalysts and materials. New combinatorial
chemistry techniques have reduced synthesis times by
allowing simultaneous generation of a large number of
chemical variants, several of which may be active leads.
Once this lead generation process is complete, the
resultant combinatorial library is subjected to high-
throughput screening techniques, one of which is HPLC.
After biological activity testing, there is still the need to
isolate the active molecules without creating a bottleneck
in the laboratory.
Lead optimization, for many compounds, requires that
only a few micrograms or milligrams of a compound be
purified to confirm the preliminary results. In this paper,
we will show straightforward HPLC strategies to devel-
oping fast gradient methods to quickly scale-up and
purify target compounds from other inactive combina-
tions
Strategies for high-throughput HPL(] analysis for
combinatorial chemistry
j. Carmody, U. Neue, R. Crowley and C. Andrews, Waters
Corporation, Milford, MA, USA
Traditionally, the search for biologically active molecules
has involved the synthesis of one-molecule-at-a-time
discovery strategies. This has proven to be a very time-
consuming and labour-intensive process for the discovery
ofnew drugs, catalysts and materials. New combinatorial
chemistry techniques have reduced synthesis times by
allowing simultaneous generation of a large number of
chemical variants, several of which may be active leads.
Once this lead generation process is complete, the
resultant combinatorial library is subjected to high-
throughput screening techniques, one of which is HPLC.
Due to the plethora of compounds generated by the
combinatorial chemistry technique, minimizing analysis
time is paramount to meeting the major challenge of
isolating the desired compound from other indigenous
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material as quickly as possible. Optimization of the
HPLC screening process to achieve shorter analysis times
is not always intrinsically straightforward. In order to
achieve compressed analysis times, there is a need to
more completely understand the effect that the column
characteristics (i.e. particle size and column length) and
the operational parameters (i.e. flow rate and gradient
time) have on the selectivity and resolution of the
separation; the resolution and the selectively being the
two characteristics of the separation most affected by
changes in the column and operational parameters.
In this paper, we will show straightforward HPLC
strategies to developing fast gradient methods to quickly
resolve target compounds from other inactive combina-
tions.
Sample dissolution and replication station for
plates from combinatorial chemistry
Gerhard Mihm, Department of Chemical Research, Screening
Support, Boehringer Ingelheim Pharma KG, Biberach, Germany
As a result of the rapidly increasing number of com-
pounds prepared in the combinatorial chemistry groups,
there is an urgent need in the chemical repositories to
optimize the processing of the samples for high-through-
put screening (HTS). Samples have to be dissolved and
aliquoted into several plates and tubes in order to transfer
them to the HTS groups. In addition, an efficient and
reliable tracking of the platemaps is mandatory. We have
designed and implemented, together with Zymark UK
and Zymark Germany, a workstation-type robotic system
based on the Zymark RapidPlate, including a robotic
arm to handle the plates. Plates are tracked by barcode
labels. Data management is via file transfer between the
workstation and the dispensary ORACLE database.
Efficient handling of compound solutions for HTS
and follow-up assays using a new robotic system
Gerhard Mihm, Department of Chemical Research, Screening
Support Unit, and Rudolf Haider, IS Department, Research
Support Team, Boehringer Ingelheim Pharma KG Biberach,
Birkendorferstrasse 65, Germany
The demands for rapid and reliable handling of com-
pound solutions for high-throughput screening activities
and follow-up assays are increasing steadily. In addition,
the numbers to be stored and manipulated in the
compound dispensaries are also increasing due to the
activities in combinatorial chemistry.
In order to meet those needs, we have implemented an
automated storage and retrieval system lbr compound
solutions in microtubes, microtubes in the corresponding
racks and microtitre plates (REMPASS). The samples
are stored in special storage racks at 4C and manipu-
lated with a 14axes robotic system. The coordinates of the
samples are kept in a dedicated database. Requests for
compounds are processed via the database used in the
compound repository for the administration of all
samples. The robotic system used for the manipulation
of the samples is presented here as well as the interface to
the dispensary database.
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Does your liquid handler pipette accurately?
James Ormand, Jimmy Brunet, Sarva Tadepalli and Cole
Harris, Glaxo Wellcome, Research Triangle Park, NC, USA
Many bioassays require organic solvents to solubilize
high concentrations of compounds, precipitate proteins,
quench enzymatic reaction, etc. Manufacturers, e.g.
Tecan, Packard and Beckman have designed a variety
of liquid handlers to automate these bioassays. Water is
the benchmark liquid used when evaluating the accuracy
and precision of liquid handling equipment. But, how
accurately does this equipment handle non-aqueous
liquids?
In this example, preparation of plasma standards from
acetonitrile stock solutions using a Tecan Genesis 150
with Logic version 1.85 revealed a problem with the
accuracy of delivering organic solvents within the normal
volume range of the instrument. The observed concen-
trations of standards prepared using the automated tech-
nique were fbund to be 15% lower across the range
when compared to manually prepared standards for two
separate runs. Gravimetric measurements revealed that
he system was only delivering 84% of the requested
volume of acetonitrile, and similar results were observed
with methanol. The solution to this problem was found in
the recently released Tecan Logic version 2.11 through
the use of liquid classes.
This poster will discuss the challenges associated with
handling non-aqueous liquids and how manulacturers,
e.g. Tecan and Packard handle these issues.
A flexible, generic robotic system that performs
protein precipitation assay for research support
j. A. Short, E. D. Lynch and T. L. Lloyd, DuPont Pharma-
ceuticals Company, Newark, DE, USA
As a drug discovery program begins to narrow the search
for a specific compound to advance into drug develop-
ment, the final candidate compounds within that re-
search class are studied in vivo in different animal
populations. Research support bioanalysis involves these
first in vivo sample analyses of a variety of closely related
compounds. These studies are characterized by small
sample batches typically 20-80 samples per compound,
where analysis of multiple compounds is often required
within a single analytical run. There are lots ofstudies for
compounds closely related in structure, therefore leading
to the generation of a large number of different standard
curves for quantitation. Sample matrices vary consider-
ably and sample volumes are often small (200tl).
Because these are the first in vivo studies with these
compounds, analysts are forced to guess rather broadly
at sample concentrations.
The investment in method development at this stage is
typically measured in hours, with almost all of the
research support work involving protein precipitation
for sample preparation. The scientists performing these
studies typically have broad responsibilities, with the
bioanalytical component only comprising a small portion
of their duties. As such, an automated platform for these
applications must have a friendly user interface such that
users can walk up and quickly run the system withAbstracts of papers presented at the 1998 ISLAR
minimal training or understanding of the automation.
The system must have a high degree of flexibility to
accommodate the method changes associated with each
set of samples between or within analytical runs.
Such a system has been created and implemented.
Features of this system will be presented. Some of the
more formidable challenges to this approach, encoun-
tered in working with the Factor Xa class ofcompounds,
will be explored and discussed.
Automated HTS monitoring technology: laser
fluorescence methodology for fingerprinting food,
beverage and pharmaceutical products
R. P. Gill, W. Smith and R. H. Selinfreund, Lion Laboratories,
Saybrook, CT, USA
The absorption of light by matter is related to molecular
structure. Some molecules can momentarily store
energy by the excitation of electrons from the ground
state to excited singlet states. Relaxation fi’om an excited
singlet state results in fluorescence via the emission of
light at a different wavelength. The interaction of
fluorescent dyes with complex mixtures, e.g. foods and
beverages, is highly reproducible, quantifiable, and can
be used as a particularly valuable method to characterize
mixtures.
Using a proprietary library of dyes and the resulting
interaction(s) with single or multiple analytes, Lion
Laboratories has developed a method to numerically
describe fluorescent fields for foods and beverages. This
process in the most simple terms can be thought of as
mapping the fluorescent field of an analyte or mixture of
analytes via interaction with specific dyes or dye com-
binations. The dye analyte interactions may involve
complexation and]or the formation of ionic or covalent
bonds. The fluorescence utilized can be in the ultraviolet,
infrared or visible regions of the electromagnetic spec-
trum, and is expressed in a digital ttshion to develop a
multiple fluorescent profile of a mixture designated as a
fingerprint. In certain cases, this can be used as a specific
assay for a single analyte that may be either a key
ingredient or an undesirable contaminant; or more
generally, the fingerprint can be used to differentiate
authentic from non-authentic samples.
Lion has developed this process utilizing 96-well plates,
robotics and automated dilution/sampling techniques to
provide a technology (patented) to assess authenticity of
complex mixtures. Applications include spirits, bev-
erages, fruit juices, flavours, natural extracts, e.g. vanilla,
as well as individual ingredients, e.g. caffeine. The tech-
nology is also of value to characterize or fingerprint
chexnical processes, and it allows a simple mechanism
for protection of intellectual property. The poster in-
cludes an overview of test design, robotic HTS infra-
structure, sample handling and data management/
presentation.
Microadsorptive tips for
prior to mass spectrometry
sample preparation
Rich Garretson and Donald G. Sheer, Millipore Corporation,
Bedford, MA, USA; Melanie Lin, Ken Parker and Martin
Hornshaw, PerSeptive Biosystems, Framingham, MA, USA
The ability to remove salt and detergent from protein or
peptide samples at the nanogram level has become rate-
limiting in structural characterization studies. In many
cases, the high sensitivity afforded by mass spectrometry
is compromised by interfering contaminants that suppress
fragment ionization and obscure mass peaks. This com-
plication along with the difficulties associated with
microlitre volume and nanogram mass handling makes
sample preparation a significant challenge. To address
these demands, an adsorptive pipette tip containing
previously evaluated reverse phase and ion exchange
resins [J. Biomolecular Techniques (1997), 1, 0001, 0009]
is presented for direct mass spectrometry. Sample recov-
ery, fidelity and reproducibility were demonstrated using
HPLC and MALDI. The ability of these devices to
remove salt and detergents enabled the acquisition of
excellent MALDI spectra for a variety of controlled
digests.
Use of the (lytofluor 4000 microplate fluorimeter
and twister plate loading robot for high-through-
put yeast viability screens
Christopher L. Haber and James C. McGuire, Discovery Tech-
nologies, Pharmacia & Upjohn, Kalamazoo, MI, USA
Fluorescent dyes have been used extensively as indicators
of cell viability. Because of their robustness and ease of
use, they are easily incorporated into high-throughput,
whole cell screens with cell viability end-points. We have
routinely used the alarmarBlue redox indicator in such
screens and the Cytofluor 4000 microplate fluorimeter for
determining the fluorescence intensity of the samples.
Recently, a robotic plate handling arm (the Twister)
has become available for the Cytofluor 4000. Here we
describe the performance of the Twister-outfitted Cyto-
fluo in screening for least viability using 96-well and
384-well plates. The Twister currently holds up to 20
plates. The software allows multiple plate data in a single
file, and can accommodate > 20 plates per file (sequen-
tial runs of up to 20 plates each). Raw data are exported
in a variety of file formats lbr use in data processing
programs. Throughput with 96-well plates with the
Twister was 45 plates/h, 15 plates/h with 384-well plates.
This system was used to screen at 116000 compound
library against a Saccharomyces cerevisiae permeability
mutant.
High-performance
thesis and beyond
automated chemistry: syn-
Richard Gray and Clare Ruddick, The Technology Partnership,
Melbourn, UK
This poster illustrates various key features of the Myriad
Core System (MCS) and Personal Synthesizer (PS)
which were developed at The Technology Partnership
(TTP) in collaboration with seven leading pharmaceu-
tical companies. In particular, it will emphasize the most
recent developments which expand the range of chem-
istry possible, including reactions with reactive gases at
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up to 4 bar pressure and reactions involving distillation
steps. The new automated liquid-liquid extraction
module is also described. This poster addresses the most
common solution phase work-up procedure in a con-
venient and efficient instrument.
The automated synthesis of a solid phase Ugi
library
George C. Morton, Timothy F. Herpin, Joseph M. Salvino,
Jonathan S. Mason, Sheng-Yuh Tang, Gerald McGeehan and
Richard Labaudienier, Lead Dis.covery, Rhone-Poulenc Rorer
Central Research, Collegeville, PA, USA
A novel resin-bound isonitrile was used in the Ugi multi-
component reaction to generate a library of dipeptoid
carboxylic acids. One thousand, one hundred and thirty-
six compounds were synthesized on two ACT 496 MOS
robotic synthesizers. A Tecan RSP 5051 liquid handling
robot was used to transfer a slurry of the resin into the
ACT reaction blocks and also to transfer the final prod-
ucts. The automation protocol will be presented along
with the general reaction scheme.
Managing combinatorial chemistry analytical
data using an electronic notebook interface and
open database technology
Tom Clemow, Howard L Cannon and Curtis Marx, Groton
NeoChem, Acton, MA, USA
Improvements in combinatorial organic synthesis have
made producing thousands or tens of thousands of
compounds per month practical. Today’s HPLC, MS
and NMR instruments accommodate quantitative or
qualitative analysis of thousands of samples per month
with a limited number of instruments.
Existing data management tools, however, cannot easily
or automatically combine data from multiple analytical
techniques, or with structural, activity and compound
location data. Without suitable management software,
analytical data are disconnected from other drug dis-
covery data. Future improvements in synthetic, analyti-
cal and screening automation will exacerbate this
bottleneck in drug discovery.
The NeoLink/cc software automatically imports chroma-
tographic, MS and NMR results into ORACLE or any
ODBC compliant database. This database also contains
links to other drug discovery data including chemical
structure, compound location and activity. The software
interface includes powerful data query and data display
functionality. The notebook interface provides a common
viewer for raw and procesed data from different analy-
tical techniques. Once data are associated in a notebook
format, they can be saved and forwarded to other
researchers to support rehearsal or production syntheses.
Data extraction and association can be automated using
data templates for routine data analysis and reporting.
This software tool effectively links analytical QC data to
chemical library and HTS databases for more compre-
hensive and timely access to chemical synthesis intbrma-
tion.
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A powerful new screening technology utilizing
capillary electrophoresis
Y. M. Dunayevsky, L. G. Rashkovetsky and D. E. Hughes,
Cetek Corporation, Marlborough, MA, USA
A new screening technology based on laser-induced
fluorescence with high-resolution capillary electrophor-
esis (CE) has recently been developed. This technology
greatly enhanced the ability to discover valuable ’hits’ in
complex mixtures, e.g. natural samples (crude extracts,
broth), combinatorial chemistry libraries and combina-
torial biology mixtures. Examples using several targets
and discriminating between strong, moderate and weak
binding hits will be shown. With natural samples, these
very sensitive CE assays can follow active fractions
through multiple purification steps, and typically find
numerous hits per active sample.
A high-throughput luciferase gene reporter assay
system: LucLiteTM, LumiGount(R) microplate lu-
minometer and TwisterTM universal microplate
handler
Li Li and Steven Lane, Packard Instrument Company, Meriden,
CT, SA
Reporter gene assays have been widely used in studying
regulation of gene expression. The bioluminescent luci-
ferase reporter assay has become the method of choice in
reporter gene studies, especially in many drug-screening
applications, because it is the most sensitive, simple and
rapid assay for quantitating transcriptional activity. In
this paper, we present a simple procedure or automating
a luciferase reporter gene assay using the LucLiteTM
luciferase reporter system, the LumiCount(R) microplate
luminometer and the TwisterTM universal microplate
handler. The LucLite reagent kit provides true long-lived
glow luminescence signal for detection and a simple
homogeneous assay procedure. Tle LumiCount micro-
plate luminometer enhances these advantages with a
high-performance detection design, allowing detection
of firefly luciferase at the attomole concentration level
in both 96- and 384-well microplate formats. The signal
is linear over an extended enzyme concentration range of
five orders of magnitude using one instrument setting.
The same attomole level sensitivity and extended linear
detection range are achieved using the Twister universal
microplate handler, allowing for an increased sample
throughput and walk-away convenience. The resulting
performance in sensitivity, throughput, accuracy and cost
advantages makes this combination of reagents,
instrument and plate stacker an ideal system for micro-
plate-based gene regulation studies and high-throughput
drug-screening applications.
New techniques in solid-phase synthesis: gaseous
chemistry for parallel array synthesis
Thomas J. Baiga, Charybdis Technologies, Carlsbad, CA,
USA; Gregory P. Roth, Boehringer Ingelheim Pharmaceuticals,
Ridgefield, CT, USA
As part of an on-going program to further develop
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Charybdis teamed up with Boehringer Ingelheim to
advance the state-of-the-art solid-phase synthesis para-
digm. These new techniques involved gaseous chemis-
tries, where active synthesis reagents were delivered to
the Reaction Block as gases using the Calypso Gas
Manifold. Three new chemical methodologies were de-
veloped: Pd-catalysed aromatic nitro group reaction, Pd-
catalysed hydrogenolysis as a Wang resin linker cleavage
protocol, and Pd-catalysed Still-type carbonyl insertion.
These chemistries were originally developed manually in
the Calypso Reaction Blocks. But to further enhance and
explore this methods development program, several
automation platforms have been integrated, notably the
Iliad PS2 Personal Synthesis System, the Calypso 4X
Shaker Workstation and the RapidPlate
(R) multichannel
pipetter. The RapidPlate represents the newest product
in an extremely versatile line of workstations to be
integrated with the Calypso System.
Throughput organic synthesis for discovery
library production: the automation of the Ugi
multi-component condensation reaction
Traci Trotman, Charybdis Technologies, Carlsbad, CA, USA;
Chris Hulme, Rhone-Poulenc Rorer, Collegeville, PA, USA
Faced with the daunting task of automating the synthesis
of more than 3000 compounds per week, scientists of
Rhone-Poulenc Rorer have integrated several tech-
nologies into a unique combinatorial chemistry produc-
tion facility. Utilizing the Ugi multi-component
condensation reaction as a probe for molecular diversity
in their discovery libraries, the RPR Team has success-
fully automated most solid-phase synthesis operations.
Charybdis Technologies Calypso Reaction Blocks (96
well, filtration variant) were initially prepared with
synthesis resin. This task was automated by integrating
the Calypso RM onto a RapidPlate
(R) 96 locator plate,
and simultaneously dispensing resin materials as an
isopycnic slurry. The Calypso RBs were drained, washed
and prepared for synthesis on the Iliad PS2 personal
synthesis system. The Iliad delivered reaction solvents
and diversity reagents to the 96-well reaction blocks.
Reaction incubation was performed off-line to maximize
the compound throughput for the task-specific work-
station network.
Use of the nQUAD technology for nanolitre dis-
pensing in microplate applications
Dennis Stachelek, Don Rose, Tony Lemmo and Tom Tisone,
Cartesian Technologies, Irvine, CA, USA
Cartesian Technologies has developed a nanolitre, quan-
titative aspirate and dispense (nQUAD) technology for
use in microplate applications. The technology couples
the precision displacement resolution of a stepper motor-
driven syringe pump with the rapid actuation capability
of a micro-solenoid valve. The result is a dispenser
technology with the following features:
quantitative dispensing of nanolitre volumes (down
to 4 nanolitres);
dispense in a non-contact mode for easier mechan-
ical alignment;
rapid dispensing speed; and
wide dynamic dispense volume range (low nanoli-
tres to mid microlitres).
Increasingly, there is interest in using high-density micro-
plates (384 wells and greater) for screening applications
to achieve higher throughput and reduce plastic and
reagent costs. Because these microplates have a well
volume as small as 2 lal, the typical dispense volume is
in the sub-microlitre or nanolitre range. With its ability
to quantitatively dispense in this volume range, the
nQUAD technology has found recent application as a
useful technology in microplate applications. This poster
will show the mechanism, characteristics and practical
issues in applying the nQUAD technology to microplate
screening applications.
Integration of a 384-well plate washer with a
robotic plate handler
Jim Breunig, Mitotix, Cambridge, MA, USA
The advantages of the 384-well plate format for high-
throughput screening can be greatly enhanced with the
capability to automate the delivery and removal of the
plates to the instrument. A recent integration of a
Skatron Instruments, EMBIA 384-well plate washer with
a Zymark Corporation TwisterTM universal microplate
handler was tested and evaluated. Results of ease of set-
up, ease of use, throughput, reliability and overall
suitability for the high-throughput laboratory are pre-
sented and discussed.
Multifunctional robotics compatible washer for
high-throughput screening
Paul Held and Gary Barush, Bio-Tek Instruments, Winooski,
VT, CrSA
Today’s research requires that instrumentation be cost
effective, reliable and easy to use. Bio-Tek Instruments
would like to introduce the Elx405 multifunctional
washer. Because today’s assays require multiple washing
formats, the Elx405 can be configured in three different
modes of operation: (i) a combination of 96-well or 384-
well washer manitbld; (ii) a 96-well only manifold; and
(iii) a 96-well version with magnetic bead capabilities.
The 96/384 manifold has a unique design (patent pend-
ing) which provides for independent control of aspirate
and dispense tube location and height, enabling bubble-
free fluid-dispense and overflow protection in 384-well
plates. The 96-well manifold allows for overflow protec-
tion, as well as ’bottom washing’, and standard features
have been included to make the Elx405 washer robotics
friendly and ideal for automation. Features, e.g. vacuum
detection, are provided to ensure that the vacuum pump
is switched on and vacuum vessel are connected. Flow
protection alerts the user to an interruption offlow to the
dispensing manifold. The washer has a waste detection
device, which through software prevents overflow of
waste into the vacuum pump. Because buffer is drawn
from reservoirs by suction from a syringe pump, pressur-
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ized buffer containers are not required for operation. The
optional buffer switching module allows for the automatic
switching from up to four different buffers. The washer
also has a separate priming trough to allow for automatic
priming (’autoprime’) and automatic rinsing (’autorinse’)
during wash procedures. The Elx405 is robotics friendly
with RS232 connections that allow communication with
several robotic devices. Assay protocols are capable of
being downloaded from a separate PC or programmed
through a washer keypad. Besides being versatile, the
washer is lightweight (< 13.5kg), compact (41 x 41 x
26 cm) and capable of 110 and 220V operation.
An automation-friendly high-performance and
high-throughput (HTS) assay detection system
integrated with a high-capacity microplate hand-
Ier
Amer E1-Hage, Carl Wright, Mike Biros and Doug Modlin,
LJL BioSystems, Sunnyvale, CA, USA
An overview of the design, performance and features for
laboratory integration of the Analyst
TM will be pre-
sented. Analyst
TM is LJL BioSystems’ new multi-mode
detection platform for high-throughput screening (HTS)
for accelerated drug discovery. The instrument was
designed from conception to operate in an automated
laboratory environment as p_art of a workstation or
robotics line set-up. Analyst has already been success-
fully installed and integrated into several automated
laboratories with robotics systems and workstations with
minimal effort. An integrated microplate stacker option
to the instrument improves throughput and efficiency,
and a robot-ti’iendly microplate carrier reduces both set-
up time and process errors. In addition, a graphical user
interface that runs on a local host in Windows 95 or NT
facilitates system set-up and method development. We
will highlight in this poster the integration of the Analyst
with the Zymark TwisterTM microplate handler as a
specific example.
Test liquid handling systems from 4tl to 3251
quickly and easily with Path(heckTM sensor
Evelyn McGown, Kirk Schroeder and Dean Hafemen, Molecular
Devices Corporation, Sunnyvale, CA, USA
As part of a laboratory quality system, pipettors and
dispensers should be checked regularly to verify perform-
ance. Gravimetric methods for pipettor calibration are
adequate for single-channel devices but are impractical
for multichannel pipettors. Spectophotometric methods
typically require an added dye, which is convenient and
potentially erroneous because the dispense volume of the
liquid may be affected by the dye. The Molecular
Devices SPECTRAmax(R) Microplate Spectrophot-
ometers employ a patented PathCheck sensor which
offers a fast, reliable method lbr checking performance
of multichannel pipettors and dispensing stations using
dispense reagent, without added dye.
The performance test is performed by dispensing the
reagent into a 96-well microplate and measuring the
optical pathlength in each well. Precision is calculated
directly from the pathlength data and accuracy is
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determined by reference to a pathlength/volume stan-
dard curve. Dispense volumes between 30 gl and 325 lal
can be tested directly with typical standard deviations of
0.003cm (or 0.5gl in a half-area well microplate). A
difference method enables volumes from 4 lal to 30 gl to
be accurately tested with a standard deviation of
0.015 mm. The method is fast, accurate and ideally suited
to test automated liquid handling stations, especially 96-
channel pipettors.
A novel fluorescent HTS platform using homo-
geneous miniaturized cell- and bead-baseds
assays for drug discovery and development
Elana Swartzman, Sheri Miraglia, Lolita Evangelista, Kenton
L. Lohman and Pau Yuan, PE Biosystems, Foster City, CA,
USA, David M. Heffelfinger, Ed Goldbery and Bala S. Manian,
Biometric Imaging, Mountain View, CA, USA
Detecting cellular biochemical or molecular events in
reaction to exogenous drug stimuli in live cells has always
been a challenge to drug development groups. Homo-
geneous or ’no wash’ assays on live cells have been
especially difficult and have lacked the sensitivity needed
for effective evaluation of biological events. A number of
instrument and biochemical technologies have been
developed to address this issue. Most have concentrated
on elucidating drug effects on live cells earlier in the drug
screening process. In most cases, however, high-through-
put formats have been sacrificed for the increase in
information.
In a co-development effort, PE Biosystems and Biometric
Imaging have developed a new, two-colour, fluorescence-
based instrumentation which enables the user to rapidly
screen large numbers of drug candidates on live cells
using homogeneous assay formats in standard microplate
formats up to 1536 wells. The instrument is based on the
laser scanning microvolume fluorometry technology de-
veloped by Biometric Imaging tbr cytometric analyses.
Homogeneous receptor/ligand studies, signal transduc-
tion mechanisms and cell death determinations can all be
made rapidly on live cells. Data are collected for each
individual cell in the scan area, which is unique for high-
throughput instrumentation. The two-colour format
provides the user with the ability to evaluate two cellular
biological events simultaneously in a single cell in a high-
throughput mode.
In addition, two-colour homogeneous, bead-based ver-
sions of standard biochemical assays previously devel-
oped for solid phase technologies, e.g. immunoassays, are
easily accomplished on this platform.
We will describe the specific, homogeneous, biochemical
systems and instrumentation that we have developed to
investigate the effect of candidate drugs on live cells in
high-throughput formats.
Detecting the binding of fluorescent neuropeptide
Y to GHO-KI cells expressing NPY receptor sub-
types using fluorometric microvolume assay tech-
nology (FMAT) in a high-throughput, cell-based
formatAbstracts of papers presented at the 1998 ISLAR
Sheri Miraglia, Elana Swartzman, Lolita Evangelista, Kenton
Lohman and Pau Yuan, Perkin Elmer Biosystems, Foster City,
CA, USA; Bala Manian, Biometric Imaging, Mountain View,
CA, USA
The development of molecules that mimic, enhance and/
or block the interaction of bioactive peptides with cell
surface receptors, in particular the subset represented by
the 7-TM (transmembrane) G-protein-coupled recep-
tors, is a major focus of pharmaceutical development.
The rapid identification ofpotential leads is a crucial first
step in this process and would be greatly facilitated by
simple, homogeneous, high-throughput screening assays.
Currently, the scintillation proximity assay provides a
homogeneous format for monitoring receptor-ligand
interactions; however, the assays are all bead-based and
require the use of radioactivity. We have developed a
technology, fluorometric microvolume assay technology
(FMAT), which enables detection in the red region and
is compatible with various formats, including 96-, 384-
and 1536-well plates. Using this technology, we are able
to detect the binding of fluorescent neuropeptide Y to
transfected cells expressing either the neuropeptide Y
type receptor or type 2 receptor, and identify the IC-
50 values of competing unlabelled peptide. Ligand
binding assays were pertbrmed in high-density, low-vol-
ume 384-well plates. This technology can be used in a
cell- or bead-based format, and is unique in that it is
simple, homogeneous, high throughput and non-radio-
active.
Performance of Labsystems’ microplate instru-
ment interfaced with the Assist microplate hand-
ling device
Ron Gulka, Labsystems, Franklin, MA, USA
The Labsystems’ Assist microplate handling device easily
and economically automates the manipulation of 96- and
384-well plates. The Assist can be interfaced to a wide
range of Labsystems’ microplate instrumentation, includ-
ing dispensers, washers and readers. Highlighted will be
the performance specifications of the Assist and the
Multidrop 384 dispenser, Wellwash Ascent plate washer,
Multiskan Ascent photometric reader, Fluoroskan Ascent
fluorometric reader, and Fluoroskan FL combination
fluorometric and luminometric reader.
A versatile, fully automated open-access work-up
station designed to serve the needs of the rapidly
expanding field of multiple parallel synthesis
(MPS)
Gordon A. Hamlin, Zeneca Pharmaceuticals, Alderley Park,
Macclesfield, Cheshire, UK
The rapid growth of multiple parallel synthesis (MPS) in
our laboratories has created a demand tbr a robust, easily
accessed automated work-up procedure, as the manual
work-up of large numbers of small-scale reactions is both
time consuming and tedious. Manual work-up is also a
rate-limiting step in the generation of large numbers of
compounds for test.
Work-up in chemical organic synthesis consists of a series
of post-reaction operations designed using differential
chemical properties to remove excess reagent or starting
material, reagent products and, where possible, reaction
by-products. Careful consideration of post-reaction op-
erations as a clean-up step can obviate the requirement
for purification. This has been an attractive feature of
some MPS at Alderley Park, which we have attempted to
address with automated procedures.
Generally, work-up can be resolved into four operations:
filtration, solvent addition (dilution, trituration), wash-
ing and separation (partition). The ordering and selec-
tion of these four basic operations through an operator-
controlled interface will, therefore, create a generic work-
up program. This presentation will describe the flexibility
and power of a Zymate XP-based generic work-up
protocol as well as the safeguards necessary for its smooth
operation as an open-access facility. Thought is also given
to the development of a condensed, bench-top system for
use in a standard chemistry laboratory fume cupboard.
Solid phase extraction as an efficient method of
purification for automated synthesis
Marian Young, Harold Weller, Jacques Roberge and Walter
Ruediger, Bristol-Myers Squibb Pharmaceutical Research Insti-
tute, Lawrenceville, NJ, USA
As pharmaceutical companies continue to search for new
drugs, automated synthesis is becoming more widely
used. These synthetic procedures often produce com-
pounds that need purification before they are submitted
tbr biological screening.
Solid phase extraction (SPE) is an automated high-
throughput purification method that was originally used
for concentration of biological and environmental
samples. We have modified these methods to be useful
for purification of synthetic compounds. Most commer-
cial instruments using SPE cartridges process one sample
at a time. Because each sample can take 20-60 min for
purification, a modest automated run of 96 compounds
can take several days to purify.
We have developed with Bohdan an instrument that is
capable of processing a set of 96 compounds purifying
eight samples at a time. This instrument has the versa-
tility of collecting up to three fractions for each sample,
and using either 3 or 6 ml cartridges. This capability has
allowed the purification of 288 compounds in a single
day. We designed the graphical interlSce to be very user
friendly, as we encourage walk-up use of our automated
equipment. The development of instrumentation, mod-
ification of SPE resins and purification methods used to
make SPE a useful and efficient method of puriting
libraries of compounds will be discussed.
Automation and library production at Selectide
Eric Wegrzyniak, Kirsten Bjergarten, Marry Vanderstelt and
Daniel Schirlin, Selectide, a subsidiary of Hoechst Marion
Roussel, Tucson, Az, USA
In order to complement the well-known ’one bead one
compound’ or ’split and mix’ technology originally
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developed by Selectide, we have designed a system for
high-speed synthesis (HSS) of combinatorial libraries in
commercially available 96-well plates. Libraries are
produced either as large collections of individual
compounds, or as low-complexity mixtures, thus drama-
tically decreasing the need of deconvolution for hit
structure determination while maintaining a high-syn-
thetic throughput.
The system uses a workstation approach. A Zymate XP
robotics arm distributes the plates among local robotics
units performing various organic synthesis tasks, where
multiple microtitre plates are processed simultaneously.
The tasks include resin dispensing, reagent addition,
incubation, washing and cleavage. A description of the
different workstations, along with the strategies followed
for libraries synthesis on solid phase and/or solution phase
will be discussed.
User-friendly top level software for controlling an
automated combinatorial chemistry system
Ton Jenneboer and Will Kuijpers, NV Organon, Oss, The
Netherlands
At the end of 1996, a fully automated robot system was
installed in our research laboratories to support combi-
natorial chemistry activities. The heart of the system is
formed by LaMOSS (Labotec Modular Organic Syn-
thesis System), a synthesizer capable ofperforming liquid
phase as well as solid phase chemistry. LaMOSS is based
on Zymark technology. Its features include nozzle-based
handling of reagents, building blocks, solvents and resin-
slurry (including split/pool procedures), temperature
control of the 48 reaction vessels and collection of the
products in standard 16 x 100mm tubes. These tubes
can be transported with a shuttle to a Zymark XP robot
where evaporation and liquid-liquid extraction can be
performed.
LaMOSS is provided with pre-programmed basic func-
tions which perform the most simple tasks (e.g. nozzle-
movement, set switches). We have added so-called unit
operations, each of them performing a specific task using
the basic functions (e.g. add liquids, transfer tubes). Until
recently, the actual synthesis was programmed in the
recipe which contains a list of unit operations accom-
panied by the selected parameters. This recipe had to be
written prior to every synthesis. The disadvantage of this
set-up was the complex and time-consuming program-
ming of the syntheses.
Initially, LaMOSS was connected as local controller to
the XP-controller to enable communication between
both controllers in case of tube transport. In this set-up,
syntheses were programmed entirely in the LaMOSS
TM controller using EasyLab for Windows and could be
started either from there or by the XP-system. As a
consequence of this set-up, manual interference in one
system (stop and abort) resulted in a stop of the other
system as well.
These experiences encouraged us to find a better way of
controlling LaMOSS. This paper describes the develop-
ment of user-friendly top level software, running on a
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standard PC and controlling LaMOSS through the
normal EasyLab high-speed connection.
This connection became available to us with the use of
Zymark Tools for WindowsTM, and relatively straight-
forward user-interface was developed in Visual BasicTM
for writing and controlling a synthesis. Because this
approach demands a direct connection between PC and
controller, the tube-transfer to the XP-system is now
organized with the use of switches and inputs in both
systems.
The top level software consists of a Synthesis Editor for
writing and running the recipe and an Event Viewer for
showing the controller status. The chemist chooses the
desired events via buttons and pop-up windows, and the
program shows the recipe in ’chemical’ language. Sub-
sequently, the program adds the appropriate unit opera-
tions and parameters to be sent to the controller. In this
way, the controller is handling a complete unit operation
by itself, so there still is a minimum of communication
time involved.
Automated method transfer: ’a tale of two labora-
tories’
Timothy A. Diehl, Janssen Pharmaceutica, Titusville, NJ,
USA
’It was the best of times, it was the worst of times’, as
Dickens wrote, captures the implementation process of
automation systems in non-R&D laboratories. Imple-
menting automation in a quality assurance laboratory
has always been a difficult task due in part to the
technical and managerial roadblocks. However, as auto-
mation becomes an integral part of many corporations’
strategies to increase efficiencies, the inertia to overcome
these obstacles is being gained. The use of technology
transfer process helps to determine if any analytical
method developed on a research instrument will work
on a production instrument. However, these require-
ments may also complicate the implementation process.
Factors both positive and negative that influence the
implementation of a global automation plan will be
discussed. Experiences encompassing logistics, manage-
ment, regulatory, compliance, communications and tech-
nology transfer will be discussed in this presentation.
Development and transfer of an analytical chem-
istry workstation to a manufacturing site
Craig Bender, David Otto, Alan Wickman and Mark Schweit-
zer, Searle Research and Development, Skokie, IL, USA
Automated analytical chemistry workstations can be very
useful for a quality assurance lab at a pharmaceutical
manufacturing site. Workstations can provide increased
sample throughput, increased turnaround times, and
more accurate and precise results. Methods can be
developed by Research and Development labs and
transferred to the manufacturing site on the automated
equipment. Automating the analysis using the same
sample preparation parameters can ensure results that
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An automation project was undertaken by Searle Re-
search and Development and Bohdan Automation
(Mundelein, IL) to automate the analysis of dosage form
assay and content uniformity testing. Two identical
systems have been developed, one for Research and
Development, and one for our manufacturing site in
Puerto Rico. Each automated system can process up to
30 samples by serial processing using the following steps:
(1) dispense media into sample tube;
(2) vortex to dissolve;
(3) filter sample aliquot;
(4) dilute samples; and
(5) inject sample onto HPLC.
System validation and transfer activities to Puerto Rico
are currently underway. Protocols and methodologies
have been developed by Searle R&D. This presentation
will describe the activities that have taken place during
the transfer of the automated system to Puerto Rico.
High-throughput bioanalytical mass spectrometry
using 96-well solid phase extraction
ohn aniszewski, Monica Swyden and Hassan Fouda, Drug
Metabolism Department, Pfizer Central Research, Groton, CT,
USA
Coupled with HPLC/atmospheric pressure ionization--
mass spectrometry, microtitre 96-well plate technologies
for sample and liquid handling have dramatically in-
creased our drug metabolism bioanalytical throughput.
Over the past several years, we have focused our efforts
on developing and integrating several bioanalytical
throughput-enhancing approaches for use in our depart-
ment. These efforts have led to the development of
standardized protocols for 96-well solid phase extraction
methods development, assay validation and sample
analysis for the quantitation of drugs and metabolites
in biological fluids. The protocols feature the routine use
of X-Y liquid handlers from the outset of methods
development through assay validation and sample analy-
sis. The liquid handlers are used for standard curve
preparation and sample transfer to the 96-well format.
Standardized dilution templates and plate layouts are
used, reducing the need for customized software pro-
gramming. The SPE plates are processed using a pro-
grammable 96-well pipettor, the Quadra 96. Once an
analytical method has been developed, a single analyst
can routinely process 400-600 samples in about 4 h. Most
of the analyst’s time is taken in set-up and sorting of the
samples prior to and while using the workstations.
Evaluations of validated assays using automated
solid-phase extraction with LC.,/MS/MS for ana-
lytes in plasma
Naijia H. Huang, Lloyd R. Whitfield, John R. Kagel and David
T. Rossi, Parke-Davis Pharmaceutical Research, Division of
Warner-Lambert Company, Ann Arbor, MI, USA
Automated solid-phase extraction (SPE) using a Rapid-
Trace workstation was developed with LC]MS/MS to
qualify a drug candidate in plasma for blood lipid
regulation. The validated method was characterized for
precision (interday and intraday precision of 7.0% and
9.8%, respectively) and accuracy (interday and intraday
relative errors of-t-2.7% and :t=6.7%, respectively), and
recovery (greater than 90%) over a calibration range of
5-1000ng/ml. The method was used to assay over 2500
samples, standards and controls in support of toxicology
studies in mouse, rat, dog and monkey. Benefits of the
automation included saving of analyst time, and decreas-
ing exposure of analyst to biological and chemical
hazards. Evaluation of automation performance (includ-
ing failure rate, carryover and throughput benchmarks)
will be discussed. Adaptation of the method for use with
96-well technology and insights gained during the study
will be presented.
Determination of 264W94 and 2169W94 by LC/MS/
MS using a 96-well SPE: a comparison of semi-
automated and fully automated approaches
Lisa St. ohn-Williams, Glenn A Smith, Ifathryn B. Ifenney and
John A. Dunn, Glaxo Wellcome, Research Triangle Park, NC,
USA
The compound 264W94 is currently under investigation
as a hypercholesterolemic agent. An automated method
for the quantitative determination of the drug and its
demethylated metabolite, 2169W94, in human serum
was developed and validated using solid phase extraction
in the 96-well plate format. The extracts were analysed
using electrospray ionization LC/MS/MS. The com-
pounds are isolated from human serum using Waters’
OasisTM HLB extraction plates. The calibration range of
the assay was 0.1-100 ng/ml.
Two different automation approaches were validated
and compared. The original method was developed using
a Packard Multiprobe 104DT and vacuum manifold.
The method was later transferred to a fully automated
Zymark XP robotics system interfaced with a Tecan RSP
8051 liquid handling workstation. The latter system uses
centrifugation to carry out the solid phase extraction, and
is the first example demonstrating this technique using
these new robotics systems.
The validation data from both automated systems con-
firm that the specificity, precision and accuracy of the
assay are sufficient to support the quantitation of
264W94 and 2169W94 in clinical trial samples. The
problems encountered during the development of the
automated methods and the validation results will be
presented. The two approaches will be compared, and
their unique advantages and disadvantages will be
discussed.
A comparison of pressure- and vacuum-based
automated 96-well SPE systems for the LC-MS/
MS bioanalysis of haloperidol in plasma
Jaap Wieling, Jelle Hempenius, Ruud J. J. M. Steenvoorden
and Jan H. G. Jonkman, Pharma Bio-Research International
B. V., 9470, AE Zuidlaren, The Netherlands
Since the introduction of liquid chromatography with
tandem mass spectrometric detection (LC-MS/MS) as a
quantitative technique in the field of routine bioanalysis,
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sample preparation became the new throughput-limiting
step in the entire analytical process. Manual solid-phase
extraction (SPE) is a particular example of this situation.
We have implemented various instrumentation for auto-
mated 96-well SPE (SPE96), either based on positive
pressure (Hamilton Microlab) or based on negative
pressure (vacuum) (Packard MultiProbe) for pipetting
clinical samples, and the application of conditioning,
washing and elution solvents on the solid-phase bed
(3M Empore extraction plates) and subsequent flow
through. To compare and validate both principles, we
have implemented an SPE procedure tbr an LC-MS/MS
method for haloperidol in human plasma on the Hamil-
ton and Packard systems, keeping the experimental con-
ditions for the extraction on the two systems as similar as
possible. Besides validation results on precision and
accuracy, some other per|brmance aspects were assessed,
e.g. throughput, number of assays to be repeated due to
blockings, human intervention, detection of levels and
carry-over.
The validated calibration range was from 0.100 to
50.0 ng/ml. The inaccuracy and imprecision were below
15% at all concentration levels and for both systems,
although the coefficients of variation for the vacuum
system were significantly better (two-sided F-test). This
was most likely caused by the Hamilton’s flow detection
system using a pressure-drop monitor, leading to drying
out of the wells and subsequent channelling and irregular
wetting of disks, and thus less reproducibility within an
SPE96 plate. Secondly, the larger carry-over of the
pipetting equipment of the Hamilton system caused less
precision.
Although the sample throughput of the Packard systems
may be higher as a result of a four-needle configuration,
current commercial systems cannot operate fully unat-
tended; technicians must interfere by changing 96-well
plates, positioning sample collectors underneath the
plates, and transfer of the sample collectors to the HPLC
systems. The Hamilton operates slower (current system
applies only one needle), but operates fully unattended.
AllegroTM: moving the bar upwards
Mary Jo Wildey, R. W. Johnson Pharmaceutical Research Inst.,
Raritan, NJ, USA, Carol Ann Homon, Boehringer Ingelheim
Pharmaceuticals, Ridgefield, CT, USA, and Burleigh Hutchins,
Zymark Corp., Hopkinton, MA, USA
At the 1995 Society for Biomolecular Screening Con-
ference, the term ultra-high-throughput screening
(UHTS) was introduced. UHTS was to be the next
generation of screening and was defined as the screening
of 100 000 samples in an assay in a day. This new rate of
screening would be required to test the million-com-
pound libraries enhanced through combinatorial chem-
istry of the future. At that time, most highly automated
systems had a throughput of 100 plates a day. The major
limitations tbr these systems were the robotic designs and
the time of analysis. Cost was to be a major factor for the
screening of these new million-compound libraries. To
maintain costs, new technologies would need to be
incorporated into the screening solution. Miniaturization
and nanotechnology became the new buzzwords. How-
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ever, it soon became evident that even conversion from
96-well formats to 384 was not going to be as simple as
expected. New designs tbr 384-well microtitre plates are
evolving to address the problems identified with the
earlier designs, e.g. wicking and pipetting with multiple
tips. It was appearing that UHTS would have to wait for
better plate designs, remodelled pipettors to specifically
address 384-well formats and lower pipetting volumes,
and changes in quantitation techniques to imaging. In
the meantime, the issue ofhow to manage and move the
plates required for 100000 compounds needed to be
addressed. In the fall of 1996, an idea emerged around
the simple concept of platemovers
TM instead of robots,
and reducing the HTS process to a series of individual
steps separated by time. A robotic concept now called
Allegro
TM by Zymark would be a series of fully indepen-
dent modules working together in a process-like manner
very similar to an assembly line. The simple motions
required of the platemovers
TM would allow them to
move faster, make them far more dependable and much
easier to program. These modules could be easily re-
ordered, passed or linked to create new procedures. The
system would be fully enclosed to allow control of the
assay environment in terms of gas, temperature and
humidity. This new modular robotic system completely
processes 1200 plates of a 96-well design in 24 h. Alle-
gro’" will also allow for easy incorporation of new
technology-based modules. As this new technology is
incorporated, the future throughput in terms of total
number of wells could be even higher. Once Allegro
TM
has finished its initial test programs, assays that are
compatible with a 384 format will be started. This
presentation will present the Allegro
TM system applica-
tions as well as an evaluation of this new concept as it
pertains to performing UHTS and its integration in the
research environment.
(fell-based assay miniaturization for ultra-high-
throughput screening
Ilona Kariv, Anthony M. Mafia and Kevin R. Oldenburg,
DuPont Merck Pharmaceuticals, Wilmington, DE, USA
Recent advancements in the fields of combinatorial
chemistry and genomics greatly increased the size of
chemical libraries and the number of targets against
which they are screened. This substantial growth in
library size and target number necessitates changes in
high-throughput (HTS) screening. One solution is to
miniaturize the HTS format, thus providing a possibility
to increase throughput and save reagent cost. Miniatur-
ization involves designing and adapting current HTS
assays to high-density lbrmats, either 1536-well (5gl)
plate for cell-based assays or 6144-well (0.7 gl) plate for
soluble enzyme assays. Although some progress has been
achieved in the last few years in adapting bacterial and
protein-based screens to high-density formats, mam-
malian cell-based assay modification still remains a major
challenge. One of the primary obstacles is the ability to
dispense cells in a small volume, while maintaining cell
integrity. This is especially true for functional assays
relying on transcriptional machinery to express genes of
interest. Extensive assay run time creates the additional
problem of liquid evaporation. In this study, we selectedAbstracts of papers presented at the 1998 ISLAR
a cell-based assay utilizing luciferase reporter gene under
control of the gene of interest 5 binding site in a stably
transfected Jurkat T cell line, as a model. The objective
was to identify specific inhibitors of the expression of the
gene of interest. Limitations and advantages in adapting
this assay to high-density format, 1536-well plate, and
technical considerations and challenges are further dis-
cussed in this report.
TM ExtremeScreen meeting the challenges of ultra-
high-throughput screening
Michelle Palmer, Mark Roskey, Bonnie Tillotson, Neil Carlson,
Mike Nemzek and Irena Bronstein, PE Tropix, Bedford, MA,
USA
Extreme high-throughput screening (EHTS) at rates
beyond 100000 compounds/day is an emerging tech-
nology. It is diflicult for a screening laboratory to
dedicate resources to all the new screening technologies
and incorporate them into their working environment.
The challenges ofEHTS include selection of technologies
and formats, the associated learning curve, adaptation of
existing assay methodologies to new formats, and re-
quired infrastructure and logistic issues.
Tropix ExtremeScreenTM is a new concept that provides
a three-tiered approach to delivery advanced chemilu-
minescent screening technologies. First, ExtremeScreen
provides proprietary chemiluminescent dioxetane screen-
ing reagents to meet the stringent demands of yielding
high-quality data across a wide range of assay types in a
single platform at very high-throughput levels in a cost-
effective manner. Second, ExtremeScreen rapidly devel-
ops custom screening assays tbr deployment on screening
systems at the user’s site. Third, ExtremeScreen is a
complete service to perform advanced screens at rates
above 100000 samples per day with in-house or custo-
mer-supplied libraries, bringing extremely rapid turn-
around on large or small screening projects. The
combination of the three elements significantly contri-
butes to accelerating the drug discovery timeline.
Technology, logistics and common sense: chal-
lenges and opportunities in high-throughput
screening
John Major, Lead Discovery Department, Zeneca Pharmaceu-
ticals, Alderley Park, Macclesfield, Cheshire, UK
High-throughput screening (HTS) is a key process in
pharmaceutical lead identification. Screening through-
puts of tens of thousands ofcompounds per assay run are
typical. Advances in chemistry are providing opportu-
nities to access increasingly large compound sets. This
development is fielling a trend towards greatly increased
screening capability. Effective systems need to be devised
for storage, retrieval, formulation and supply of com-
pounds to screens. HTS operations need to be fuelled
with novel drug targets, and screening systems capable of
efficiently delivering leads rather than hits are urgently
required. There is a need to deploy the principles ofhigh-
throughput screening against downstream functional
biology and the drug adsorption, metabolism and tox-
icology bottlenecks. These requirexnents present signifi-
cant challenges in relation to assay technology, screening
logistics, automation and management of the processes.
The challenges and the opportunities they present will be
discussed.
Leveraging a discovery organization: the Sepracor
experience
ames R. Hauske, Sepracor, Marlborough, MA, USA
Discovery at Sepracor is shaped by the strategic impera-
tives of the ICE portfolio, i.e. our drug discovery efforts
are directed toward the therapy areas of inflammation,
pain and urological diseases. We have attempted to
enrich the highly successful ICE( approach by broadly
defining each of the therapeutic areas to include a wide
range of molecular targets with potential therapeutic
advantage over existing approaches. These approaches
are ultimately directed at disease with unmet, undermet,
medical need and significantly large patient populations.
By focusing our efforts on the core competencies of
synthetic chemistry, medicinal chemistry and combina-
torial chemistry, we have developed a proprietary and
highly diverse corporate file ofsmall, drug-like molecules.
Our strategy of developing collaborative relationship
with selected biotech partners with proprietary molecular
targets, or proprietary platform technology, in the thera-
peutic areas of strategic interest to Sepracor provides a
means to most effectively leverage our ever-expanding
corporate file of drug-like molecules. Combining our
unique skills in combinatorial chemistry and medicinal
chemistry with the highly evolved HTS competency and
proprietary molecular targets of each of our biology-rich
collaborators has driven the rapid implementation of our
drug discovery strategy. We will describe the approach
that we utilized to define the portfolio of Sepracor
Discovery, as well as the implementation of the discovery
programs.
Leveraging your technology investment: maintain-
ing the competitive edge in drug discovery
Ralph Infantino, anine Schwedes, Margaret Reynolds, Mimi
Rivera and Mel Reichman, OSI Pharmaceuticals, Uniondale,
NY, USA
Recent advances in drug discovery technologies present a
wider range of opportunities that require careful evalua-
tion for compatibility with existing systems. This can be
an arduous task for an established facility with much
invested in the current infrastructure. Because HTS is no
longer the rate-limiting factor in discovery, established
R&D sites specializing in it must carefully weigh its
options and aim for rapid return on investment. Issues
that must factor into decisions on increasing throughput
and capacity must address questions involving how
quickly a screen must be completed versus the pace at
which assays are formatted and validated. Moreover,
solutions should address how to leverage the resources
required for lead follow-up, medicinal chemistry, com-
pound acquisition and pharmacology. We will describe
our philosophy and operational approaches that allow us
to derive maximum value from our formidable existing
infrastructure dedicated to HTS, while keeping pace with
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emerging technologies ad the ever-increasing need to
increase throughput and capacity.
An overview of the methods validation process
Patrick J. Faustino, Centerfor Drug Evaluation and Research,
Office of Pharmaceutical Science, Division of Product Quality
Research, Laurel, MD, USA
The methods validation process involves three areas:
validation, evaluation and verification. These terms are
defined by the Analytical Methodology Technical Com-
mittee (AMTC) of the FDA within the current revision
under ’good guidance practices’ (GGPs) of the 1987
guidance: ’Guideline for submitting samples and analy-
tical data for methods validation’. The three areas out-
line the regulatory responsibility of the drug sponsor and
the agency. Validation is the responsibility of the drug
sponsor to prove the analytical method will work accord-
ing to its intended purpose. Evaluation is the responsi-
bility of the review chemist. Evaluation is the analysis of
the drug sponsor’s validation of the analytical method.
Evaluation also defines what analytical procedures and
performance parameters are required and specified in the
1987 guidance and the USP chapter 1225. Verification is
the responsibility of two FDA field laboratories to estab-
lish the suitability of the method for regulatory purposes.
Further discussion of the methods validation process will
also include ICH guidelines and FDA’s Chemistry
Manufacturing and Controls committee’s review practice
and guidance development.
Development and validation guidelines for auto-
mated methods automation subgroup of the phar-
maceutical and analytical sciences group
John Stanley, SmithKline Beecham Pharmaceuticals, Harlow,
Essex, UK
The Automation subgroup of the PASG in the UK was
set up at the beginning of 1996 and has since grown to
include representatives from pharmaceutical companies,
vendors and contract laboratories. The purpose of the
group was to exchange experiences on robotics and to
influence vendor developments. However, it soon became
clear that the most immediate need, and probably
the greatest challenge, was to construct guidelines for
the development and validation of automated methods.
Individual companies had gone through parallel
development processes that relied on hard won
experiences and considerable expertise. The novice robot
user is faced with a very steep learning curve, so
considerable effort could be saved by the pooling
together of the collective expertise already available in
the group.
The resulting document contains detailed recommenda-
tions for single and composite dosage form assays,
degradation/impurity profiles and dissolution testing,
and is suitable for any instrument that is capable of
performing these tests in a laboratory environment. The
presentation highlights the important issues arising from
the work of the PASG automation subgroup.
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Automated method validation of an oral product’s
assay and content uniformity
Samuel Barrera, Rafael Cruz, David Ledn and Carlos Rivera,
Bristol-Myers Squibb Company Bristol Laboratories Corporation,
Quality Control, Mayaguez, PR, USA
QC challenges for improving productivity, reducing
cycle time, improving efficiency and maintaining a high
level of regulatory compliance require a high application
of advanced technology. On the other hand, the con-
centrated efforts ofAR&D in drug discovery, a fast pace
of newly launched products and the constraints of cost
reduction have led to more independence of QC labs in
method validations. This situation triggered the QC
initiative undertaken at Bristol Laboratories Corporation
in Mayaguez, PR to validate the TPWI workstation for
the automated sample preparation of BuSpar assay and
content uniformity based on previous applications of the
QC lab in Evansville of this same company. This project
has opened the door for other applications that will result
in higher throughput, efficiency and other benefits of
technology for success.
Keys to successful method validation and method
transfer in the R&D environment
dTon P. Sadowitz and Sam Li, Barr Laboratories, Pomona, NI,
USA
Automated techniques for sample testing are readily
increasing in the R&D environment. With this increase
comes the need for pertinent validation that streamlines
the path for use of these techniques, and addresses the
means to transfer these methods to other areas or
departments, either locally or remotely. This presenta-
tion will address the prevailing philosophies, techniques
and protocols of the R&D automated method develop-
ment team, and how they affect the automated method
validation of solid dosage forms of assay, content uni-
formity and impurities testing along with the transfer of
these methods to the QC environment.
Automation and robotics--the key elements in
global standardization of physical test methods
Ramasamy Tamilarasan, Paul L. Morabito and Jonathan ,.
Zieman, The Dow Chemical Company, Midland, MI, USA;
Paul D. Hazelwood, The Dow Chemical Company, Sarnia,
Ontario, Canada
Companies have realized that they have to embrace the
world as their workplace and marketplace in order to
grow and compete in the global market economy. They
are sprinting into the global marketplace at record clip,
propelled by technology. The next-generation companies
will be so integrated with the world that they will be non-
national rather than multinational.
Globalization of products is forcing the companies to
globally standardize the production and quality control
test methods. This paper describes the development and
implementation of the robotic automated systems for
tensile, FLEXuRAL, hottack and heat seal tests of
polymeric materials. These systems handle rigid polymer
samples of 6-8 inches long, polymer film samples of 6-13Abstracts of papers presented at the 1998 ISLAR
inches long, as thin as 0.001 inch. The other capabilities
of the systems include reading barcode labels, measuring
sample thickness and communicating to the testing
instrument. These automated systems enabled the global
standardization of the test methods, improve the produc-
tivity by nearly 150%, and provide consistent and
quality results in a cost-effective manner.
A new standard for polyurethane physical prop-
erty testing
Steven E. Robbins and Michael E. Rusak, Air Products and
Chemicals, Allentown, PA, USA
Polyurethane foam is found in hundreds of applications,
including furniture cushions, automotive seating, appli-
ance and construction insulation, and carpet underlay.
Polyurethane foams are created by reaching isocyanate,
water and polyol in the presence of catalysts, surfactants
and potentially other additives. The resultant polymer
morphology resembles a sponge, a non-homogeneous
material with a varying cell size distribution. While the
cellular nature of the foams is exploited to meet certain
performance characteristics, physical property measure-
ments must be based on samples large enough to
represent average behaviour.
Industry standards, e.g. ASTM, define sample handling,
conditioning, shape and size, as well as manual testing
methods, for each physical property desired. Our experi-
ence has shown that these manual methods are subject to
operator and device variability.
During the past decade, we have developed standard
automation approaches to improve sample handling,
instrument control and data acquisition, while develop-
ing a collection of reusable hardware and software com-
ponents. Data reliability and reproducibility have
improved greatly for each of the methods we have
automated. These methods include density, airflow, com-
pression set, Japanese wet set, tensile-tear, and dimen-
sional stability. This presentation will illustrate test
improvements and some of the automated techniques
developed to achieve them.
Custom bar code label printing software for
laboratory automation
Saul Llamas and Stephen Dokoupil, Automation Laboratory,
Helene Curtis Innovation Center, Unilever Home and Personal
Care, Rolling Meadows, IL, USA
Barcodes are prominently used in the retail marketplace
and have found many uses in other fields, including the
area of laboratory automation. Jars, prototype contain-
ers, test tubes, sample vials and microtitre plates are just
a few of the items that are now bar coded. Bar codes are
key to a successful robotics automation system. Bar codes
allow a robotics system to identify and track samples. Bar
codes also enable the use of embedded protocols within
the bar code number that identify the tests to perform on
a sample. In addition, bar code labels allow placement of
human-readable data, providing users in the laboratory
with quick descriptive information on a particular test
sample.
Two approaches used by Helene Curtis for printing bar
code labels will be presented. The software presented are
two custom bar code label printing applications devel-
oped in-house; one written in LabVIEWTM and the
other in Visual BasicTM. A comparison of LabVIEWTM
and Visual BasicTM software for application development
will be discussed, along with techniques on interlacing
custom software to the ZebraTM bar code printer.
Interfacing databases with the bar code software will
also be covered.
An automated sample preparation for determina-
tion of total siloxanes in shampoo products using
inductively coupled plasma (ICP) spectroscopy
Kyoko Ida and M. Karita, Procter & Gamble Far East,
Higashinada-ku, Kobe, Japan
This paper describes an automated sample preparation
for the determination of total siloxanes in shampoo
products using inductively coupled plasma (ICP) spec-
troscopy. A fully automated robotics system requires only
setting blank sample tubes on the racks and putting
products into these tubes manually. Robot preparation
gives us higher efficiency in extraction and lower RSD
than current manual preparation.
Currently, we can analyse 30 samples per day by the
manual method at KTC. However, our new automated
robotics method is expected to have the capability of
analysing 50 samples per day. Therefore, this automated
robotics method will supply us with much higher speed
for determination of the siloxane percentage in shampoo
products.
The analytical data sets demonstrate accuracy, precision
and reproducibility of the sample preparation. Linearity,
accuracy and precision ensure the validity of the robotics
method. The method has a linearity working range from
0 to 500ppm (correlation coefficient, R 0.9999). The
method gives sufficient recoveries, R 101 + 1%. Rela-
tive standard deviation (RSD) is 0.42%.
Database mining and knowledge discovery in
modern drug research
G. M. Maggiora, M. S. Lajiness, D. W. Elrod, M. A. Johnson
and T. R. Hagadone, Pharmacia & Upjohn, 301 Henrietta
Street, Kalamazoo, MI, USA
A growing trend towards automation within the phar-
maceutical industry has led to an explosive growth in the
rate, amount and types ofdata that must be dealt with in
modern drug research. Within the space of only a few
years, highly sophisticated technologies have transformed
drug screening; DNA, RNA and protein sequencing; and
chemical synthesis increasing throughput in these key
areas by a thousand-fold or more. Computers provide the
only effective means for managing this growing flood of
data. But managing data is not enough if the knowledge
embedded within it is to be obtained. It is here that
newly emerging techniques of database mining and
knowledge discovery, already having considerable im-
pact in many areas of business and industry, may also
play an important role in pharmaceutical research. In
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high-throughput screening, e.g. numerous biological
assays are run against corporate compound collections
typically of several hundred-thousand compounds or
more. Such a database represents a watershed of un-
discovered biological knowledge, but the database must
be properly ’mined’ if the knowledge within is to be
realized. The discovery of relationships, rules and pat-
terns in databases of this size is, however, a daunting task
at best and cannot be addressed with many of the tools
used successfully on much smaller datasets. The talk will
present a brief overview of the salient issues in database
mining and knowledge discovery that are applicable to
pharmaceutical research. Several examples will be pro-
vided that illustrate how these methodologies can be used
to extract new knowledge that can potentially expedite
the drug discovery process.
Quality control for high-throughput screening
Michael W. Lutz and Jay Gill, Glaxo Wellcome, Research
Triangle Park, NC, USA
Robotic systems for biochemical assay introduce a new
set of requirements for analysis of quality control data.
The precision and accuracy of liquid dispensing robots
and complete robotic assay systems must be determined
and monitored. To properly interpret data, assay varia-
bility must be quantified. Automatic detection of gross
errors, systematic errors and random errors is necessary
for systems that run continuously.
This presentation addresses statistical methods and prac-
tical concerns involved in quality control analysis for
high-throughput screening. After a review of methods,
examples are given that demonstrate how quality control
statistics are applied in the area of high-throughput
screening. Finally, the recommendations for best prac-
tices are discussed.
Maximizing information content in combinatorial
libraries
Steven L. Gallion, ArQule, Medford, MA, USA
The process of library design and interpretation of SAR
data should be guided by the ability to extract substan-
tive information during each design cycle. The successful
management of data during the entire drug discovery
process is a function of the ability to not only track and
store data, but to formulate and refine hypotheses that
result in at least a semi-quantitative rationale for lead
optimization. This presentation will discuss the issues and
strategies involved in the design ofcombinatorial libraries
to deliver maximal information content. Examples in-
clude the rational selection of building block components
using a combination of medicinal chemistry expertise,
computational analyses, crystallographic structures and
diversity assessment tools.
From functional genomics to prototype drugs
Dale S. Dhanoa, 3-Dimensional Pharmaceuticals, Exton, PA,
USA
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Advances in genomics continue to discover new explora-
tory targets for drug development in large numbers. At 3-
Dimensional Pharmaceuticals, we have developed a
powerful drug discovery system that integrates our
proprietary technology components of Probe Libraries,
ThermoFluor(R)=AE High-Throughput Screening, Di-
rected Diversity@=AE and Informatics. The strategy
for finding small molecule prototype drugs for functional
denomics targets using our integrated drug discovery
systems will be described.
Inhalation product testing: automated sample re-
covery from Cascade Impactors
Phil Waters, Glaxo Wellcome, Research Triangle Park, NC,
USA
The Andersen eight-stage Cascade Impactor is a stan-
dard device used to characterize the aerodynamic par-
ticle size distribution of metered dose inhaler (MDI) and
multiple dose powder inhaler (MDPI) products. The
manual test typically requires assembly, dosing and
separation of the Impactor unit; rinsing each stage/plate
component into separate collection containers; adding
sufficient volume of solvent; and sample assay (typically
by HPLC). This paper discusses a device developed by
Glaxo Wellcome that automates the time-consuming
rinse steps associated with the recovery of drug from
Cascade Impactor stages. A detailed description of the
hardware and software configuration is presented, along
with analytical validation results for products currently
tested using this system.
Enhanced decision-making from analytical auto-
mation
Harnath Doddapaneni and John Jushchyshyn, SmithKline
Beecham Pharmaceuticals Research & Development, Upper
Merion, PA, USA
Automation initiatives have been traditionally viewed as
a resource-reducing tool. The ability of automation to
generate high-quality, reproducible and correlative data
has been largely overlooked. This paper will present
long-term dissolution data generated on development
batches of drug product which compare manual ap-
proaches versus a segmented automated approach. The
data produced using automated methods reduce or elim-
inate variation due to slight changes in manual tech-
niques which occur from analyst to analyst over a period
of years in a typical stability study. While the outcome of
a stability exercise is equivalent, the data produced using
automated procedures allow management decision-mak-
ing at a much earlier stage in the stability cycle when
compared to other approaches which are inherently more
variable.
Development of an automated assay for sustained
release tablets using the TPW-II Workstation
John C. Lynch, Zeneca Pharmaceuticals, 1800 Concord Pike,
Wilmington, DE, USA
Automated composite and content uniformity assays for
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TPW-II Workstation. Use of the TPW-II has reduced
sample prepartation and analysis time from over 4 h per
sample to under 30 min per sample, significantly increas-
ing sample throughput. Because the TPW-II homo-
genizes, filter and dilutes each sample, analysts spend
less time preparing samples and can focus on other
responsibilities.
In order to successfully and efficiently automate methods
using the TPW-II, analysts need to evaluate the cap-
abilities and limitations of the workstation as well as the
method development costs versus the advantages
(throughput, labour, safety) achieved by automating a
specific assay.
Our experience developing automated sustained release
assays has enabled us to develop a method development
template for the TPW-II. A simple, step-wise approach
has been defined to guide automated method develop-
ment and provide the analyst with a reasonable estimate
of the work required at any given stage of product
development. This presentation will discuss this method
development approach using specific examples from the
automated sustained release tablet assay.
Development of an automated liquid store to
improve sample management in the lead discov-
ery process
Sue Holland, Peter Aperghis, Melanie O’Neill, Clive Battle,
Tim Linsdell and Martin Sykes, Glaxo Wellcome Research &
Development, Medicines Research Centre, Stevenage, Hefts, UK
The potential for identifying new lead compounds in the
drug discovery process is increasing through the use of
faster and more efficient approaches to high-throughput
screening (HTS) and larger, more diverse compound
collections. The rapid developments in robotic HTS
systems and the expansion of sample libraries through
combinatorial chemistry place demands on traditional
approaches to sample supply which have made this
element of the lead identification process rate limiting.
In order to maintain pace with HTS, a sample supply
strategy is required which will respond rapidly to screen-
ing requests, provide the flexibility screeners want, and
maintain control and accountability for the quality of
samples produced. To achieve these goals, Glaxo Well-
come has developed an automated sample storage,
retrieval and processing system with the capacity of 3
million samples and an output rate of 15 million samples
per year. The automated liquid store (ALS) comprises an
environmentally conditioned sample storage facility and
an input/output buffer integrated with three liquid
handling robots (LHRs). The system will perform sample
replication and discrete sample picking from 384-well
source blocks into either 96- or 384-well microtitre plates.
The scale of this facility has called for an industrial design
concept which is modular to allow reconfiguration of the
LHRs to meet future business needs whilst maintaining
the core storage and retrieval infrastructure. This pre-
sentation will review the role of the ALS in the GW
sample supply strategy, its principle elements and func-
tions, and the approach taken to managing the project.
A robotic compound dissolution system for the
Pearl River Research Compound Bank
Kevin Olsen, Robotocist, Research Compound Bank,
Ayerst Research, Pearl River, Y, USA
Wyeth
In order to make more compounds available to high-
throughput screening researchers, the Pearl River
Research Compound Bank and the Wyeth Ayerst
Biomedical Engineering Department collaborated on
the construction of compound dissolution and distri-
bution robots.
The machines are modified industrial gantry robots and
are controlled with a Visual Basic interlhce running on a
PC. Other than the basic robot, all hardware and soft-
ware development was developed by Biomedical Engin-
eering. By standardizing upon and then lnodifying a
basic platform, the engineers used this project to develop
the expertise that was applied to subsequent projects.
The machines were designed to process 92 compounds
per hour. Data entry is completely automated through
the use of bar codes on both the compound samples and
microplates. Liquid handling was engineered so that
dissolved compounds would be completely utilized, and
there would be no residual aliquots at the end of the run.
The units have been extremely reliable. During the fall of
1996, they compiled a record of only three mechanical
failures in 75 000 samples.
Validation of 11 compound delivery to dry plates
using the Zymark RapidPlate
Brent T. Butler, Joan Frezza and Julie J. Tomlinson,
Department of Molecular Biochemistry, Glaxo Wellcome, Re-
search Triangle Park, NC, USA
The quality of data generated in screens may be com-
promised by the instability of compounds delivered to
those screens. ’Just in time’ dilution of compounds will
help to maintain the stability of these compounds. The
ability to delivery gl of compound in neat DMSO to a
variety of target plates is the basis for just in time
compound delivery and paramount to increasing the
quality of screening data generated in those targets. This
also eliminates a dilution step in the compound handling
system, thus decreasing the time spent preparing com-
pound plates for the numerous targets being screened.
Results of experiments on various plate types indicate
that Zymark RapidPlates located on the compound
handling robot in the Molecular Biochemistry Depart-
ment, RTP are able to dispense gl of DMSO reliably
and accurately. The c.v. for all plates tested were less
then 10%, with accuracy between 95 and 110%. This
capability will allow compounds to be delivered to
targets just in time, which will help to maintain the
stability of these compounds. The compound handling
robot will run control plates at regular intervals to
monitor RapidPlate function.
Use of a Zymark XP system for multiple com-
pound formatting tasks
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Richard Spann, Molecular Pharmacology, Berlex Bioscience
Richmond, CA, USA
The Zymark XP laboratory automation system provides
a versatile technology that can be fully upgraded with the
latest enhancements at desired intervals. The modules
include a Zymark XP arm, a Master Lab Station II, a
Power and Event Controller, a Fully Automated Cap-
ping Station, a RapidPlate-96 and two Storage Carou-
sels.
The architecture is standard System V with operating
system version 2.5. The interface PC is running Windows
and the Zymark Utilities package. Previous versions of
the Zymark OS only allowed I/O interactions with the
System V controller disk drive or selected files on the
hard drive via Easylink. Using functions supported under
the Zymark Utilities, data I/O is now possible directly
with any available drive.
The system is being used to support compound format-
ting and distribution for high-throughput screening
(HTS). The setup can perform four different activities:
dissolution of vials of compound then transfer to 96-well
plates; transfer from vials ofsolubilized compounds to 96-
well plates; dissolution of compounds in vials; and
consolidation of plates containing single compounds per
well into plates containing 10 compounds per well. The
plates with 10 compounds/well can then be used in HTS
assays. The matrix strategy employed allows for an
efficient means to identify HTS hits.
Laboratory data management in the QA environ-
ment
Tricia Chen, Novartis Pharmaceuticals, E. Hanover, NJ, USA
Data management is a significant challenge for the
Pharmaceutical Quality Assurance organization. The
myriad of regulations imposed by the FDA and DEA
and their subsequent translation into business practice
affords the industry many technical challenges with
respect to managing the data. From the point of data
generation in its completely raw form to its fully pro-
cessed and final resting places, the data undergo several
transformations and multiple moves.
At the lowest level, the commonplace business response is
to utilize a data acquisition system to control the
analytical instruments and to ensure that the collection
of laboratory data follows strictly defined (in-house)
guidelines. The twin concerns of data integrity and
auditing can then be addressed by relegating a collection
of routine low-level tasks (e.g. data entry, checking,
storage and retrieval) to the discipline imposed by com-
puter processes. For better control and efficient main-
tenance, a networked data acquisition system is
recommended strongly instead ofstand-alone integrators.
At the next level, we find the LIMS software with its two
primary roles, i.e. to coordinate/orchestrate the testing
and to centralize the generated data. When all three
stages of the process are properly structured, i.e. (i) the
automation of data captures; (ii) the transfer of the data
via networked (interfaced) laboratory instruments; and
(iii) the centralized storage of the test data, the audit-
ability and trace-ability issues surrounding the data
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capture can be fully addressed. This approach to data
integrity can provide management with a high degree of
confidence in their business data, and the ability to
respond in a timely manner to external regulatory
agencies.
At the third (top) level, the global needs of the business
can be addressed. Today’s business climate is fraught
with corporate mergers, increasing process regulation,
new reporting constraints, and software that simply does
not cut it anymore. All of these circumstances are
compelling from the standpoint of initiating business
process re-engineering projects. Projects directed at the
data collection level preserve the viability of the business
on the day-to-day operational level and serve to lay the
groundwork for utilizing the data in more creative ways.
Projected directed at cross-department sharing of data
(e.g. QA laboratory data with that of manufacturing), or
data sharing globally within a department serve to create
new business efficiencies. Such large-scale projects, e.g.
those of data warehousing, can be viewed as both
strategic and defensive when consideration is given to
the preservation of historical data.
Utilizing ACCESS to efficiently manage data in a
quality control microbiology laboratory
C. R. Bierman and T. M. Kajs, The Procter & Gamble
Company, Mason, OH, USA
The quality control constituent of the Health Care
Microbiology Department at Procter & Gamble is
responsible for microbial content testing (MCT) and
preservative challenge testing (MST) of all health care
products developed at the facility. MCT and MST are
required testing for product release and expiration data
determination. Put simply, data accumulated from these
two analyses, over time, determine the microbial stability
profile for each health care product. These data are
stored in the data documentation.
DDR is a system built on ACCESS software, which
manages MST and MCT data in an electronic, fully
searchable format. It was developed using the collabora-
tive efforts of the Microbiology Department and Com-
puter Management Systems.
Prior to the inception of DDR, the department tracked
all data in hard copy. As tests were completed and
verified, data for each sample were entered into a control
laboratory information management system. Data entry
proved to be time consuming and cumbersome. This
system did not offer a means of searching MST and
MCT data to the microbiologists, the primary owners of
the information. Microbiology’s need for capturing total
products stability was critical; therefore, the DDR system
was developed to help streamline work processes, increase
the department’s data management capability, and
provide electronic retrieval capability.
Using a custom-designed compound tracking
system to facilitate the automation of the produc-
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L. Cameron, C. Garr and L. Schultz, MDS-Panlabs, 11804
North Creek Parkway South, Bothwell, WA, USA
The desire for faster drug discovery led to the implemen-
tation of combinatorial methodologies for small-molecule
synthesis. In 1995, MDS-Panlabs and Trpos began a
collaboration to produce the Optiverse Library, a
parallel synthesis library composed of> 140 000 diversity
designed compounds. We have implemented a purifica-
tion process such that highly purified compounds will
join the Optiverse
TM suite ofcompounds. In doing so, the
information explosion associated with the process re-
quires special attention. The challenge becomes tracking
this information and maintaining the compound-data
link which is accomplished using a custom-designed
compound tracking system (CTS) database. The focus
of this presentation will be on the CTS and how it
facilitates the modular high-throughput processes.
Integrating good statistical practice (GSP) in HTS
information management
Frances P. Stewart, SmithKline Beecham
R&D, King of Prussia, PA, USA
Pharmaceuticals
The integrity of assay data is a quintessential construct in
the success of the HTS paradigm in drug discovery. As
technology increases in both high-throughput combina-
torial synthesis and ultra-high-throughput screening,
assay information management must evolve to address
the increasing amounts of assay data. The software
integrated with laboratory robotics to capture and store
the data must include the functionality to alert the user
when statistical tests detect erratic results or shifts due to
poor process control or instability of reagents across time.
At SmithKline Beecham Pharm., the IT infrastructure
that supports high-throughput screening implements
components within our screening data management
application that monitor the quality of the data and
alerts users to intervene when poor data quality is
suspected. Baseline control limits are established for all
HTS assays as part of the development criteria before
these assays progress to the ’live’ status of production
runs. These limits are used to flag bad data, which
enables users to cancel the data and continue screening
or to suspend screening until the source of the problems
are identified and corrected. This ensures that false
positive/negative rates are minimized and that data
posted to the corporate DB is valid. Our philosophy
towards data regulation and an overview ofour screening
data management software are discussed.
The development of a dynamic user interface for
drug discovery operations
Ralph Infantino, Ildefonso Belliard, Chris Waller and Mel
Reichman, OSI Pharmaceuticals, Uniondale, NY, USA
Data management for drug discovery poses a variety of
challenges to an informatics group. Unlike certain
’mature’ classic business operations, e.g. accounting or
purchasing, the operations model for drug discovery is in
its infancy and varies greatly from one company to the
next. Commercial packages for HTS data management
require substantial customization. As needs change, a
continuous cycle of applications development follows.
The information management system that complements
drug discovery operations must keep pace with the
dynamic nature of R&D. We will provide an overview
of our drug discovery informatics system. The modules
are developed utilizing a combination of industry-stan-
dard development tools, third-party components, Oracle
and ISIS as a database back-end, and a novel interface
concept. This system is meeting our current needs to
track HTS and associated downstream data flow. It is
also poised to meet future requirements for closer track-
ing of lead progression.
The use of TRAP for lead structure identification
M. Kozlowski, Telik, S. San Francisco, CA, USA
TRAP is a proprietary technology that is based on
understanding the biochemical description of a molecule
and using that information in concert with structural
descriptors to minimize the number of assays required to
find lead compounds for pharmaceutical targets. TRAP
complements the drug discovery process by providing an
efficient and inexpensive way to identify lead compounds
for targets that are not amenable to a high-throughput
screening (HTS) format. TRAP is also an efficient way to
identify lead compounds and validate targets that have
little pharmacological data. Terrapin employs TRAP, as
well as computational, medicinal and combinatorial
chemistry, to find families of high-affinity compounds
for pharmaceutical targets. The TRAP biochemical
description of a molecule is derived from experimental
data. Competitive binding fluorescence polarization (FP)
assays are used to determine the affinities of compound
for a diverse panel of proteins. A high-throughput screen-
ing system has been designed around our FP assays to
ensure the rapid addition of affinity data to our TRAP
database. This presentation describes the unique aspects
of Terrapin’s process of lead structure identification.
Discovery and optimization with large encoded
combinatorial libraries
Daniel Chelsky, Pharmacopeia, Cranbury, NJ, USA
Pharmacopeia has produced over four million com-
pounds using its ECLIPS encoding technology. These
compounds have been synthesized as approximately 85
discrete sets of ’libraries’ which can provide substantial
SAR information at both the discovery and optimization
phases of a program. Information obtained is not limited
to the primary target and can be extended to selectivity
as well as preliminary toxicity and metabolism, allowing
early choices among related compounds in a series. Case
studies as well as the integration of 1536-microwell
technologies will be described.
Making the move to
screening
384-well high-throughput
j. LaRocque, B. Czermik, N. Orlova and J. Babiak, Wyeth-
Ayerst Research, Pearl River, NY, USA
Recent advances in automation and assay detection
make the use of 384-well plates a viable solution to
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increase efficiency in high-throughput screening. We
have evaluated the use of 384-well plates to run a cell-
based receptor antagonist assay and an in vitro enzyme
inhibition assay. A comparison of each assay run in 96-
well and 384-well plates with regard to assay perform-
ance, automation, reagent usage, efficiency and through-
put will be presented.
A second-generation approach to molecular diver-
sity
j. Christopher Phelan, Axys, South San Francisco, CA, USA
The increasing sophistication and diversity of chemical
structures available through combinatorial chemistry
commensurately increases the challenge ofhow to choose
which compounds to make given limited resources. We
will discuss the problem of molecular diversity in large
screening libraries for lead discovery. We will present a
new ’hybrid’ approach for simultaneous optimization of
molecular dissimilarity (a ’negative’ property) and de-
scribe drug-like parameters (’positive’ properties)
Universal solvent exchanging device and reaction
optimization tool in organic synthesis
llya Feygin and Leslie Walling, Pharmacopeia, Monmouth
Junction, NJ, USA
Reliable and fully programmable delivery and evacua-
tion of solvents and reagents into and out of the reaction
vessels remain to be two of the biggest challenges in
automated chemical research. Another major challenge
is providing controllable temperature and level of agita-
tion independently in each of the vessels.
Results ofa joint effort between chemists and engineers at
Pharmacopeia that successfully resolved these issues will
be discussed.
A novel device with an open frame architecture, and
individually observable and accessible vessels allows for
either separate or batch processing of reactions. The
device provides controlled temperature, programmable
selection of delivered solvents and reagents, and three
different modes of agitation.
A novel side-stirring mechanism placed on individual
vessels creates a controllable, two-dimensional vortex
capable ot" effectively agitating ditlirent resins.
The rotating vessel-holding carousel provides a reliable
circular alignment and engagement with the stationary
top and bottom manifolds. This new technique of filling
and draining vessels which was enhanced by special
mating fittings has allowed for elimination of liquid
handling valves, reduction of tubing and the increase in
overall reliability of the system. This device is currently
going through laboratory testing, and it will most likely
be commercialized later this year.
High-throughput automated
using the myriad core system
organic synthesis
Nick Hird and Bill MacLachlan, SmithKline Beecham Pharma-
ceuticals, Harlow, Essex, UK
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The myriad core system (MCS) is a new automated
synthesizer developed by a consortia of pharmaceutical
companies and The Technology Partnership (TTP). It is
based on a flexible modular design and has capability for
both high-performance and high-throughput chemical
synthesis. The system incorporates several novel tech-
nologies in reaction vessel design, reagent delivery and
inert gas blanketing and is controlled by user-friendly
software that enables multi-job scheduling. A description
of the MCS and its use in the synthesis of solid and
solution phase libraries will be presented.
A chemist’s simple approach to robot program-
ming for reaction optimization: scheduling non-
identical procedures
Robert Osborne, Zeneca Pharmaceuticals, Hallen, Bristol, UK
The use of statistical experimental design in the optimiza-
tion of chemical processes requires the performance of
many pre-planned repetitive experiments and hence is an
obvious candidate for automation. The programming of
such automated sets ofexperiments is complicated by the
need to vary conditions (temperature, time, addition
rate, etc.) between individual experiments as well as
variation in the reagents used. This paper will present a
view of the particular requirements for the automation of
process development compared to lead optimization and
will present one simple approach, using standard soft-
ware, to providing the flexibility required for successful
automation in this area.
Automated dose measurement stations---valuable
players in the development of Turbuhalerc inha-
lers
Roger Appelqvist, Peter Andersson, Hans Lundba(k, Thomas
LO’gf, and Bo Olsson, Astra Draco AB, Lund, Sweden
Turbuhaler is a multi-dose reservoir dry powder inhaler
containing up to 200 doses. Within the product develop-
ment work as well as for release control at the manu-
facturing site, the entire dose interval needs to be
accessed. Automated systems are therefore required in
the accomplishment of high-quality work at a high-
throughput rate. At Astra Draco, the automation of dose
measurements started in 1985 and the development of
automated methods has since been an important part of
our R&D work. The number of robot stations has
increased from four stations in 1992 to over 40 identical
stations today, located at different sites in Sweden,
Germany and USA.
The robot stations are complex instruments which per-
form a number of tasks including sample handling, dose
quantification and evaluation of the results. Different
configurations may be used with tst transformation
procedures resulting in a highly versatile system. Experi-
ences from the development of the automated systems
will be discussed as well as different aspects of quality
assurance.
Automated moisture testing by Karl Fischer titra-
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Colleen S. Nichol, Searle, Stokie, IL, USA
Moisture testing is a major, high-volume analysis in the
pharmaceutical laboratory. Moisture analysis is used in
support of stability and formulation development. Moist-
ure content is a very important parameter in the drug
development process, because water in the drug product
or drug substance can lead to instability, as demonstrated
by product degradation, increases or decreases in hard-
ness, tiiability, etc. Therefore, the product should contain
minimal water and be stored in containers so as to reduce
or prevent water absorption into the product. The water
content is generally tested using a Karl Fischer titration.
At Searle, we have successfully automated a Karl Fischer
titration workstation. We have investigated several
methods that will increase throughput, while at the same
time decrease analysts’ preparation time. Several differ-
ent approaches to automating moisture testing of phar-
maceutically relevant samples will be discussed. Some of
these approaches are manual Karl Fischer titration in a
humidity-controlled glove box, the automated moisture
system from Bohdan, near-infrared spectroscopic
methods, and the Brinkmann moisture system. Data will
be presented to show the successes and failures of the
various moisture analysis systems examined at Searle.
A simple customized automated procedure for
sample dilution
Sharon Chang, Ian Harry and Maria Guazzaroni, Pfizer,
Control Laboratories, Quality Operations, Brooklyn, NY, USA
A high-performance liquid chromatography (HPLC)
system with electrochemical detections (EC) was utilized
to assay a low UV-absorbed drug substance and its
dosage forms. Two manual dilutions have to be made
for each sample. A Zymark BenchMate II Workstation
was evaluated to assist the Quality Operation Laboratory
in performing high volumes of sample preparation.
Several factors were considered in developing the pro-
cedures for automation.
(i)
(ii)
(iii)
(iv)
(v)
(vi)
The HPLC analysis method has a long run time.
The compound is susceptible to air.
The dissolving solvent and the diluent contain
different organic compositions.
The final sample volume changes slightly after
mixing.
There is an internal standard in the diluent.
The sample solution contains sugar and has a
different density from the standard solution.
A simple dilution procedure using the BenchMate with a
volumetric mode, without connecting it to the HPLC
system, was designed and validated to replace the
manual preparation. Instrument calibration was sched-
uled to ensure accuracy and precision of the performance.
The automated dilution procedure is not only reliable
and convenient, but also cost effective and environmen-
tally friendly.
The evolution of automation
regulatory science
and research in
Patrick J. Faustino, Ajaz S. Hussain and Karl P. Flora, Food
and Drug Administration Center for Drug Evaluation and
Research Division of Product Quality Research, Laurel, MD,
USA
Automation has evolved rapidly since its introduction
into the laboratory. Automation or laboratory robotics
were used primarily in quality assurance and quality
control laboratories, and gradually entered pharmaceu-
tical research laboratories where they currently play an
important role in the drug development and drug
evaluation functions. In many laboratories, the rate of
change is increasing as automation and research pri-
orities are being challenged by advances in technologies
that include combinatorial chemistry, novel in vitro and
in vivo assays, and increasingly sophisticated analytical
techniques. These challenges may require automation to
efficiently evaluate new molecular entities, new pre-
clinical models or novel research endpoints. Changes in
research priorities and requirements may require auto-
mation to more rapidly evolve to effectively utilize high-
throughput techniques to evaluate a complete range of
complex issues, e.g. chemistry, pharmaceutics, toxicity,
drug metabolism and drug-drug interactions.
The impact of automation and the changes in regulatory
research are equally striking. The regulatory research
laboratory has evolved from the initial use of laboratory
robotics as a tool to address safety issues, e.g. minimizing
human exposure to pathological agents, to efficiency
issues involving rapid methods development and assay
validation as research resources and priorities have
changed. Regulatory science has continued its evolution,
focusing research efforts to efficiently provide scientific
data that can facilitate regulatory decisions. Automation
is playing a key role in our laboratory’s evaluation of two
pre-clinical models, an in vitro cell culture model (Caco-2)
to determine intestinal permeability of drug substance
and drug product, and an in vivo transgenic mouse model
(TG.AC) to determine the carcinogenicity of drugs.
These research efforts supported by intramural automa-
tion resources may help in the development ofregulatory
guidelines that will aid FDA and industry in the NDA
process.
Five-year summary report documenting Bench-
Mate instrument performance preparing 650
urine samples for 2,4-D analysis
K. K. Brown and J. L. McLaurin, US National Institute for
Occupational Safety and Health, Division of Biomedical and
Behavioral Science, Cincinnati, OH, USA
NIOSH conducted an exposure assessment study that
required the development and application of a complex
clinical chemistry method for the analysis of 2,4-D in
urine. One assumption that this methods was developed
upon was that robotic automation would free up personal
work time in preparing samples, and thus enhance
sample throughput and reporting response time. Another
assumption was that robotics would improve QC and QC
of the analytical data. A BenchMate workstation was
used to automate the sample preparation. The robot
utilizes an analytical balance accurate to a tenth of a
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milligram which can be used to track the sample mass
before and after each preparation step.
For each 30-sample batch analysed during the study, the
mass data output file was transferred from the robot to a
spreadsheet and converted into a QC chart. In this Qc
chart, the volume of liquid used in each sample prepara-
tion step was calculated and plotted from the mass
record. In this way, sample preparation variables were
monitored, including the solid phase extraction cartridge
load rinse and elute volumes. Along with charting vol-
ume, other parameters were plotted, e.g. reagent transfer
efficiency, per cent water added to the organic phase for
reversed-phase SPE, and evaporative losses. Thus, every
critical parameter of the sample preparation was re-
corded and monitored. This chart was especially helpful
in characterizing the ruggedness of the new method.
By accumulating these batch charts, a BenchMate per-
formance history was charted with each new batch of
samples analysed. This performance history documented
changes in method parameters, and established a per-
formance baseline on which decisions were made about
instrument maintenance and repair. Also, these records
provided information for justifying the rejection of’out of
control’ data. This information was stored on CD for
CLIA documentation.
The BenchMate alone did not improve the response time
for delivering exposure data to workers, but it did shift
the bottleneck from sample preparation to data reduc-
tion. Using the BenchMate did improve QA and Qc of
sample analysis by documenting the preparation of each
sample. Some of the unprecedented advantages of using
the BenchMate over manual sample preparation during
this study were as follows. (i) Automatic weighing of test
tubes allowed for enhanced mathematical analysis of
effect variables with respect of their desired response.
For example, the effect of SPE loading elution volumes
on analyte recovery. (ii) After method development, that
same feature allowed the method to be characterized
more accurately. It would have been too labour intensive
for a chemist to manually weigh and record the mass of a
tube before and after every manipulation in the method.
(iii) The analytical balance confirmed that the robot can
dispense reagents more accurately and precisely than the
reported precision for disposable pipettes. (iv) Moreover,
the mass record allowed for increased electronic docu-
mentation which fulfils the spirit of CLIA’88 that re-
quests high levels ofQA and QC for human samples with
potential medical diagnostic outcomes.
The detection and quantitation of drugs in equine
serum using Zymark RapidTrace SPE modules
Robert McKenzie and Gina Dew#t, Michigan Department of
Agriculture, East Lansing, MI, USA
A method was needed to reduce the time involved in the
quantitation and confirmation of serum fluorsemide and
phenylbutazone and other drugs of interest in equine
serum.
Serum samples are placed in test tubes. Urea and buffer
spiked with an internal standard are added. The samples
are then submitted to solid phase extraction using Zy-
100
mark Rapid Trace SPE workstations. The samples are
eluted directly into appropriately labelled HPLC auto-
sampler vials which are then capped, mixed and ana-
lysed, using a C18 column and an HPLC system
equipped with diode array and fluorescence detectors.
This method of analysis eliminates most of the tedious
and time-consuming steps associated with liquid/liquid
extraction and manual SPE procedures, and circumvents
the problems associated with the instability of the named
drugs when they are being handled at low concentra-
tions. A highly reproducible procedure that requires only
the accurate allocation of the initial serum sample will be
presented.
Confirmation of the NIDA five using a single SPE
sorbent and an eight-solvent RapidTrace
TM
system
Thierry D. Mann and Michael F. Burke, Department of
Chemistry, University of Arizona, Tucson, AZ, USA
The NIDA five is a series of drugs that are most
commonly analysed in forensic cases. These drugs include
the opiates morphine and codeine, THC, cocaine, PCP,
amphetamines, and the barbiturates. It would be ideal if
there was one universal method for extracting all drugs.
This is not a realistic scenario, however, because many
drugs have drastically different properties, and in order
for selectivity to prevail, extraction methods must be
tailored to certain functionalities of molecules. It is
possible, however, to use the single mixed-mode SPE
sorbent in combination with eight solvents to achieve
high selectivity and efficiency extraction of the NIDA 5.
Although liquid-liquid extraction has been the most
common method for sample preparation for forensic
analysis, solid phase extraction (SPE) has some distinct
advantages. Studies have shown that SPE is more rapid,
economical and efficient than LLE. Surveys of NIDA-
certified drug-testing labs have shown that approxi-
mately 50% of analyses utilize SPE techniques. Cocaine
and THC analyses are by far the highest volume assays,
and although SPE procedures for these drugs are well
accepted, it is not clear that SPE methods for other
NIDA 5 are compatible with the solvents used in the
previous analyses.
This presentation will address the simplification of SPE
TM procedures using a RapidTrace automated system so
that no solvent replacement is necessary when changing
assays. The use of a single sorbent also simplifies the
extraction procedures.
Steps to automation in a contract research organ-
ization
Robert Massg and Carl Dourambeis, Phoenix International Life
Sciences, Montreal, Quebec, Canada
Phoenix International is one of the fifth largest CROs
(contract research organization) in the world, featuring
many services for the pharmaceutical industry. Part of
Phoenix’s portfolio of services, outside clinical research, is
a bioanalytical laboratory service consisting of HPLC,
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chemistry laboratories. Phoenix also has a new drug
discovery group consisting of in vivo, in vitro and analytical
drug metabolism areas. Phoenix’s service laboratory
group typically analyses large volumes ofsamples requir-
ing routine repetitive manual work.
In today:s highly competitive contract research market-
place, there is a strong need for cost reduction and
accurate analytical data reporting which reflects on the
pricing for the customer. One of the key factors to cost
reduction is automation. Although, initially, automation
requires an upfront capital expenditure, there will be
longer term benefits ariving from this type of investment,
including reproducible results, marketing ability of our
up-to-date technology, and larger sample throughput
with the same staff availability.
Phoenix has established a laboratory group called
’Sample Preparation and Automation (SPA)’ to fulfil
the necessary tasks of evaluation, implementation and
technology transfer of suitable automation workstation
platforms and robotic systems. Development of a new
type of trust in this technology appears to be one of the
larger hurdles to overcome in terms of employee accep-
tance. Another hurdle comes from the large pharmaceu-
tical companies in terms ofmethod adaptation. Phoenix’s
challenge is to adapt their developed automated method-
ology into its internal laboratories. Phoenix needs to meet
the clients’ requirements for automation technology and
still maintain a profitable edge with its capital spending.
Phoenix’s initiative in SPA as both a multi-instrument
automation development group and a virtual technology
transfer group are enabling Phoenix to maintain an edge
over the competition by answering the clients’ demands
for faster, accurate data generation and reporting.
This talk will represent the current approach to auto-
mation via SPA as well as interdepartmental coopera-
tion, and the challenges encountered. Also presented will
be key ideas learned along the way to implement
automation technology as well as how we are winning
over staff support towards the necessary evolution of
automation.
A comparison of two methods for measuring
kinase activity in a high-throughput format
Maureen Laney, David Lesikar and David Liu, SCIOS, Dept. of
Research, Sunnyvale, CA, USA
Two methods will be compared for measuring kinase
activity in vitro in a high-throughput format. A primary
consideration in choosing a method was for an assay that
would be widely applicable to a variety of kinase targets,
with minimal changes required when the specific enzyme
target changed. One method is an indirect assay which
links kinase activity through two auxiliary enzymes to a
colorimetric readout. The other method is a radioactive
assay with a biotinylated substrate. The product is
2"IM captured on the SAM’ streptavidin membrane (Pro-
mega). Reactions can be applied to the filter in a high-
density array by the use of the Biomek high-density
replicating tool (HDRT). Both methods are easily auto-
mated for high throughput.
Re-engineering an automated antiviral drug
screening: a novel approach of integrating a
high-speed pipetting robot
Rudy Willebrords and Ifoen Andries, anssen Research Founda-
tion, Beerse, Belgium, Eugy Van Gool, Labotec VV, Teralfene,
Belgium
In a continuous effort to optimize our drug screening, we
set out new goals to improve reproducibility and increase
throughput. After 10 years of faithful service, our robot
system had to be replaced and re-engineered.
A central XP-robot installed on a custom-designed track,
in a conditioned room (temperature and humidity),
remains the heart of the system. A multi-channel high-
speed robotic pipettor (Zypettor) was integrated with the
central robot to increase the sample throughput. Insuffi-
cient number of microplate and tip box positions on the
original Zypettor, with its relative slowness, forced us to
rebuild this station. We designed a new six-position
turntable for microplates and tip boxes to interact with
the Zypettor in order to increase the number of micro-
plates as well as the speed of pipetting of the Zypettor.
Plates and disposables can be positioned in a wide or
narrow orientation to allow rapid pipettng in rows of
eight or 12 by the Zypettor. This new dimension and
approach may create new opportunities in respect of
future configuration developments.
Efforts were also undertaken to expand the capabilities of
automated microplate measurements. Spectrophoto-
metric as well as fluorometric assessments were developed
to measure the viability of virus- and mock-infected cells.
The integration of a multi-reagent addition module
(Ras/Ram) and a Biotek 96-well washer were crucial
for the realization of those procedures. These experi-
mental implementations result in a flexible robot system
designed to run cell-based and enzymatic assays.
Evaluation of a transplanted Zymate microplate
system for 384-well automation
T. C. Ramaraj, Robotics & Automation--High-Throughput
Screening, Wyeth-Ayerst Research, Pearl River, NY, USA
We will summarize our efforts to implement automated
384-well format assays using a Zymate microplate
system. This Zymate microplate system was originally
designed and delivered to one of our sister companies for
automation of an ELISA format assay in 96-well format.
The system was also used tbr generation of diluted assay
plates from predilution plates. The original configuration
included a high-speed 12-channel Zypettor module for
dilution. In addition, the Zypettor was used for adding
substrate to assays and for serial dilution of compounds.
The system, with addition of pipetting stations, reagent
addition dispensers and an online reader for fluorescent/
spectrophotometric assays. An interesting aspect of this
presentation will be evaluation of the Zypettor module
for sample addition and small-volume delivery of re-
agents to 384-well plates. Our attempt to automate a
fluorescent assay in the fully integrated system will be
supplemented with data collected on throughput, effi-
ciency of plate handling and overall sensitivity of the
assay as tailored to the Zymate system.
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Automated cell assays using image analysis
Thomas Hartmann, Ribozyme Pharmaceuticals, Boulder, CO,
USA
We have developed a number of automated quantitative
procedures which allow us to perform cell-based assays,
e.g. apoptosis, cytotoxicity, drug delivery, gene expres-
sion and proliferation assays. These assays can be used in
high-density plates and are amenable to plate readers
and robotics. Signal detection using an epifluorescence
microscope provides single-cell sensitivity and a dynamic
range of at least three orders of magnitude. Automation
of the image acquisition and inaage analysis procedure
allows unsupervised scanning of high-density plates.
Applications, previously pertbrmed with conventional
plate readers or fluorescence-activated cell sorters, can
take advantage of the instrument’s specifications. In
particular, counting procedures and colocalization
studies should benefit from the increased sensitivity,
spatial resolution and multi-parameter capabilities of this
instrument.
Automated analytical characterization of com-
binatorial libraries by LC]MS
Olga Issakova, Victor Nikolaev, Shelly Wade, Stefan Walle and
Nikolai Sepetov, Selectide, a subsidiary of Hoechst Marion
Rousel, Tucson, Arizona, USA
Combinatorial chemistry was developed several years
ago as a tool used by a few companies for rapid
identification of new drug candidates. Today it is one
of the fastest growing and fastest changing research fields.
One of the biggest changes that has occurred in the field
within the last few years is the expansion ofautomation in
both synthesis and screening technologies. This change
shifted the bottleneck fi’om production ofnew compounds
to their analytical characterization.
Here we present a strategy developed in our lab for
automated analysis of libraries synthesized in different
formats (low complexity mixtures, arrays of individual
compounds, etc.). The goal of analysis is to provide
biologists with information about whether or not the
desired diversity was achieved, and give information to
chemists about the coupling success of the building blocks
in each randomization. Approximately 10-20% of the
compounds (wells) in a library designed for lead genera-
tion, and 100% of compounds synthesized in arrays at
the stage of library development or for SAR, are analysed
by LC/MS in high-throughput fashion. Examples of the
formats of data output used for the analysis will be
presented. Aspects of quantitative analysis of combina-
torial libraries will be discussed and illustrated utilizing
the most recent examples.
Brunswick, NJ, USA; Mike S. Lee, Bristol-Myers Squibb
Pharmaceutical Research Institute, Princeton, NJ, USA
Considerable emphasis within the pharmaceutical indus-
try has been directed toward acceleration of the drug
discovery-pharmaceutical development continuum. In
support of these initiatives, greater amounts of informa-
tion relevant to lead compound selection criteria will
serve to accelerate these stages. Combinatorial chemistry
is a widely applied approach for the generation of
structural diversity and increased numbers of novel
compounds with the goal of increasing the rate of novel
lead compound discovery. Typically, mixtures of com-
pounds, or ’libraries’, having predictable structural vari-
ation are tested for activity in a parallel format, thus
increasing the probability of discovering active lead
compounds. However, reliance on activity alone may
not be sufficient for selection of the best pharmaceutical
product. Pharmaceutical development issues focused on
excipient interactions, chemical stability, metabolic sta-
bility, pharmacokinetics, toxicology and chemical process
research heavily affect the commercial success of a drug.
The combinatorial approach may be extended for pro-
spective parallel analytical research in pharmaceutical
development. Combinatorial predictive development ex-
periments may be conducted in order to rapidly obtain
information relevant to early go/no go decisions based on
a wide matrix of development information. We have
utilized a predictive degradation strategy, aimed at the
identification of degradants in advance of their appear-
ance during the drug development process. We employ a
strategy using standard LC/MS profiling and LC/MS/
MS substructural analysis conditions to rapidly propose
the structures of the degradants. Based on these studies, a
degradant library is developed which includes infor-
mation on molecular structures, chromatographic
behaviour, molecular weight, UV spectrum and sub-
structure-specific MS/MS product ions of the individual
components. This library can then be used as a spring-
board for the structure dereplication and elucidation of
degradation products, impurities and process-related by-
products encountered in samples throughput the drug
discovery-development-manufacturing continuum, as
well as candidate selection. As a result, in an effort to
increase the capacity and throughput of the predictive
degradation profiling process, sample preparation was
critically evaluated. It was found that sample prepara-
tion is often very resource and time consuming, and
ultimately a rate-limiting factor. Therefore, as an exten-
sion ofpredictive models, we have developed a procedure
for automated sample preparation which involves a
Zymate robot. The utilization of these strategies as a
means of fulfilling and comparing selection criteria for a
number of potential drug candidates will be demon-
strated.
The impact of structure profile libraries on the
drug discovery-development continuum
Robyn A. Rourick and Jeffrey L. Whitney, Bristol-Myers,
Squibb Pharmaceutical Research Institute, Wallingford, CT,
USA; Kevin J. Volk, Saul W. Fink and Edward H. Kerns,
Bristol-Myers Squibb Pharmaceutical Research Institute, New
Automated predictive profiling of drug candidates
using LC/MS and robotics
Jeffrey L. Whitney, Robyn A. Rourick and Juan Cadavid,
Bristol-Myers Squibb Pharmaceutical Research Institute,
Wallingford, CT, USA; Saul W. Fink and Kevin J. Volk,
Bristol-Myers Squibb Pharmaceutical Research Institute, New
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Brunswick, NJ, USA; Mark E. Hail and Mike S. Lee, Bristol-
Myers Squibb Pharmaceutical Research Institute, Princeton, NJ,
USA
Recent analytical initiatives aimed at accelerating the
drug discovery and early development continuum have
focused on obtaining greater amounts of structural
information on potential drug candidates earlier in the
process. In our pharmaceutical research and develop-
ment laboratories, analytical strategies based on standard
and automated LC/MS methods [Rourick, R. A. et al.,
lOth AAPS Annual Meeting Proceedings (1994), Kerns, E. K.
et al., J. Nat. Prod., 57, 1391 (1994) are highly utilized to
rapidly provide this information.
Critical factors affecting the early development of a drug
include chemical stability, metabolic stability, formula-
tion development, process optimization and satty. Tra-
ditionally, these factors are only addressed in a ’just in
time’ capacity during development, quite often nega-
tively affecting critical timelines. One proactive use of
our LC/MS methods involves performing predictive
development profiles [Thompson, W. T. et al., Proceedings
of the 43rd ASMS Conference, 174 (1995)] on selected drug
candidates during the discovery process. This approach
involves intentional chemical transformation of a poten-
tial drug with a variety of sample conditions followed by
LC/MS and LC/MS/MS analysis to elucidate any new
components. Structures resulting from the transformation
of a potential drug are assembled into a structure profile
library (SPL) along with relevant source and reaction
parameters. Subsequently, the SPL is made available to
all downstream development areas for reference through-
out the lifetime of the drug candidate. In this way,
components in samples generated throughout preclinical
development and Phase I-IV studies can be rapidly
identified by referencing the SPL.
Current initiatives aimed at accelerating the predictive
profiling process involve automated analysis methods,
intbrmation management systems, combinatorial incuba-
tion experiments [Volk, K. J. et al., Proceedings of the 44th
ASMS Conference, 176 (1996)] and integrated robotic
methods [Whitney, J. L. et al., 15th ISLAR Conference
Proceedings (1997)]. These initiatives address the current
rate-limiting steps, which include sample production,
sample introduction, structure analysis and data man-
agement. Examples will be shown illustrating our LC/
MS-based predictive profiling methods and integrated
robotic method development station.
Automation and computer design in chemical syn-
thesis: a small company perspective
Paul M. Doyle, Stephen R. Hopkins and Emma Barker,
BioFocus, Sittingbourne Research Centre, Sittingbourne, Kent,
UK
Currently, there are a bewildering array of technological
solutions to the general problem of enhancing the
throughput of chemical synthesis in the pharmaceutical
and related industries. The degree of sophistication in
chemical manipulation that can be achieved is impress-
ive, although this complexity carries the penalty of cost.
For the smaller laboratory, not only must there be a wide
variety of techniques available to the chemist, but they
must be versatile and represent good value for the
investment made. At BioFocus, we are essentially a
service-based, problem-solving organization, which
means that we are presented with a wide range of other
people’s starting points. In order to meet tight deadlines,
we cannot afford to be locked to one technology, but
must quickly make an assessment of the correct technique
for the problem to hand. We use computation experi-
mental design to constrain the number of chemicals we
need to synthesize in order to achieve maximal informa-
tion (predictive array designTM). We have a variety of
automated and semi-automated synthetic methodologies
to provide both solid phase and solution syntheses, and
have constrained ourselves to high-quality end products.
Understanding the physical and chemical limitations of
the synthetic and analytical techniques allows integration
when appropriate. These issues will be addressed in the
talk, illustrated with practical examples.
Systems development strategy: a component-
based approach, the overview
Dinesh S. Thakur, Vincent W. Chen, Robi L. Banerjee,
Matthew G. Holt and Kirk J. Leister, Pharmaceutical Research
Institute, Bristol-Myers Squibb Company, Syracuse, NY, USA
A component-based framework has been developed
which facilitates software re-use and provides faster
integration oflaboratory automation systems. Implemen-
tation of laboratory automation systems by the tradi-
tional approach usually takes significant development
time as both module-level and application-level software
are written custom to a particular application. In addi-
tion, modification and adaptation of an existing system
developed by the traditional approach, to new and
enhanced applications, usually requires significant recon-
figuration to system software. This is because modifica-
tion and reconfiguration affect the way in which the
module-level software interacts with each other. In order
to reduce the development time, and build flexible and
easily re-configurable systems, a component-based frame-
work has been developed that addresses the issue of
software re-use and run-time configuration. This frame-
work is based on a services-based architecture and
supports stateless components that can be configured at
run-time. In addition, this framework supports poly-
morphic behaviour for all its components, which allows
for integrated substitution of hardware offering similar
functions into an existing system to enhance its function-
ality. Run-time configuration has an additional benefit of
making laboratory automation systems fault tolerant.
This presentation outlines the basic overview of this
framework in the context of laboratory automation
systems, introduces the concepts involved and provides
a high-level description of the architecture used to
develop this framework.
Systems development strategy:
based approach, the architecture
component-
Vincent W. Chen, Matthew G. Holt, Robi L. Banerjee, Dinesh
S. Thakur and Kirk J. Leister, Pharmaceutical Research
Institute, Bristol-Myers Squibb Company, Syracuse, NY, USA
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The technical detail of the architecture for laboratory
automation systems built using the component-based
framework will be described in this presentation. The
interactions between the system coordinator, the system
repository, system scheduler, system logger and other
peripheral components will be presented in the context
of the underlying services-based architecture. Description
of the communication interfaces between various com-
ponents of an automated system will be explained.
Several design patterns were used to develop this archi-
tecture. The influence of these patterns on the design of
laboratory automation systems will be addressed. Also,
the influence of unified modelling language on interface
design will be discussed. Integration of the system com-
ponents with the peripheral components to build an
automated system based on this framework will be
presented with emphasis on run-time configuration and
component reuse. In addition, the integration of this
architecture with enterprise applications, e.g. MS Ex-
change and MS IIS will be addressed. The development
of a laboratory component based on this framework will
also be described.
Systems development strategy:
based approach, the prototype
a component-
Robi L. Banerjee, Matthew G. Holt, W. Chen, Dinesh S.
Thakur and Kirk J. Leister, Pharmaceutical Research Institute,
Bristol-Myers Squibb Company, Syracuse, NY, USA
This presentation provides a concrete example of an
application developed using the component-based frame-
work. A sample inventory and control system was
developed for the purpose of aliquoting, distributing
and tracking biologic molecules in pharmaceutical drug
development. This presentation will provide an overview
of the workflow involved, a detailed description of the
functional implementation of the robotic aliquoting
system, and a demonstration of the application with the
real world implementation of the component-based
framework.
Accelerated discovery of cysteine protease inhibi-
tots by the high-throughput bioassay of cz-keto-
amide-based compounds created by automated
parallel synthesis
H. Cheng, M. Cullinane, K. Brinner, C. Baldino and S.
Chipman, Departments of Biology and Process Chemistry,
ArQule, Medford, MA, USA; M. Laboissiere and C. Craik,
Department of Pharmaceutical Chemistry, University of Cali-
fornia at San Francisco, San Francisco, CA, USA
Cysteine proteases have been implicated in a wide variety
of human pathophysiological conditions. This class of
enzymes can be subdivided into > 14 different families
on the basis of sequence homology, the calpain and
papain families being the most significant. We chose a
papain-like cysteine protease, cruzain, to demonstrate
how the integration of automated, parallel chemical
synthesis and high-throughput screening has accelerated
the discovery and optimization of small organic com-
pound inhibitors. Cruzain is a protease isolated from
Trypanosoma cruzi, the causative agent in Chagas’ disease.
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The peptidyl -ketoamide class ofcompounds are known
to be both cysteine and serine protease inhibitors. Using
solution phase, combinatorial unit synthesis was created
45 000 discrete -kitoamide compounds (via the selec-
tive monoacylation of diamines) that were arrayed in a
spatially addressable, 96-well microtitre plate format. To
address the effectiveness of this class of compounds
against cysteine proteases, we tested their ability to
inhibit cruzain. Initial results yielded a series of three
lead compounds with sub-gM ICs0 activity and up to
> 10-fold selectivity versus cathepsin B and a panel of
serine proteases. The structure-activity relationships ob-
served from the initial screening of the spatially addres-
sable -ketoamide array facilitated the design and
synthesis of additional compounds, that yielded further
increases in potency and specificity. The integration of
spatially addressable chemical synthesis and high-
throughput screening accelerated the process of inhibitor
discovery and optimization for the protease cruzain.
High-throughput screening--a multidisciplinary
team effort
A. E. Fletcher, M. S. Briggs, G. Foster, J. Kerby and N. Allen,
Merck Sharp and Dohme, Neuroscience Research Centre,
Terlings Park, Eastwick Road, Harlow, Essex, UK
The increasing demands on the pharmaceutical industry
to enhance the drug discovery process has led to the
introduction of automated high-throughput screening as
an ’industry standard’. However, the widespread implica-
tions of establishing such systems is frequently overlooked
by many companies and can be in some cases the limiting
factor to efficient HTS. Any successful HTS operation
requires a dedicated and committed multidisciplinary
team to ensure efficient maximum productivity. At the
Neuroscience Research Centre we have established such a
team which encompasses representatives from scientific
(Sample Repository, HTS and Tissue Culture) and sup-
port (Research Engineering, Purchasing and IT) staff.
The close interaction between the departments and the
benefits of such a team will be reviewed together with an
overview of the strategy employed for our HTS program.
Maximizing assay capability of older robotic
systems by incremental introduction of new tech-
nology to the screening laboratory
M. Elizabeth Miller, Rohm and Haas Company, Spring House,
PA, USA
The Agricultural Discovery Department at Rohm and
Haas Company has used a Zymark robotic workcircle to
perform fungitoxicity screening in microtitre plates for
about 10 years. At the time of delivery in 1988, the
system was considered state-of-the-art for handling mi-
croplate assays, and was comprised completely ofcustom-
designed stations, as microplate-handling devices were
almost unknown in those days. Since then, microplate
handling on integrated robotic workcircles has become
routine, and a variety of ’off-the-shelf’ plate handling
stations are now available from different vendors, obviat-
ing the need for custom stations in many cases. In light of
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integrated robotic systems still have a place in the
laboratory? Depending upon the demands on the screen-
ing organization, the answer can certainly be yes. We are
still using our original workcircle with custom stations,
with only some minor upgrades made to the system. In
order to accommodate newer assay procedures, however,
we have added several stand-alone workstations to the
laboratory, which are used for a variety ofwork processes
not manageable on our Zymark system. This combined
approach of using an integrated workcircle in concert
with stand-alone units has been a very cost-effective way
of enhancing our screening capabilities while continuing
to make full use of our investment in our original robotic
system.
Information--not just data: use of a robotic dis-
solution system to provide rapid graphical feed-
back to formulators
Mark J. Dryfoos, Stability, Robotics & Automation Group,
PHAD/ARD Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA
Early in the development stage of a solid dosage form,
many variants are produced. The sheer number of
samples to be tested can be overwhelming as formulators
try to achieve an optimal balance of lubricants, disin-
tegrates, coating thickness, tablet hardness, etc. Because
these samples will neither be used in clinical trials nor in
primary stability studies, a less formalized approach (i.e.
non-GMP) to their dissolution testing may be utilized.
We have adopted just such a ’second-track’ strategy in
the Stability, Robotics, & Automation Group, both to
ease the burden on the GMP Dissolution Testing Lab, as
well as to provide rapid turnaround, high value-added
results to the formulators. This capability is provided by
an automated Apparatus 2 dissolution system featuring a
Zymate XP robot with online fast HPLC. Customized
spreadsheets, macros and presentation graphics templates
allow for rapid data reduction and plotting. Several
unique aspects of the system as well as the advantages
of this approach will be discussed and illustrated.
An automated assay for ligands of nuclear recep-
tors
Richard If. Harrison, Litao ,hang, Ien Locke and Geoff
Schwartz, Rhone-Poulenc Rorer, Collegeville, PA, USA
Nuclear receptors are ligand-activated transcription fac-
tors. Their function in regulation of gene expression
makes them attractive targets for therapeutic interven-
tion in various metabolic diseases. As part of an ongoing
program aimed at regulation of these receptors, we have
developed a high-throughput assay for determination of
compounds than can bind to nuclear receptor targets of
interest. The assay is a simple homogeneous system based
on scintillation proximity protocols, different from other
SPA assays for nuclear receptors in the use of unde-
rivitized ligand binding domain, and is capable ofscreen-
ing over 50000 compounds/week. The evolution, from a
low-throughput manual assay, to semi-automated, and
finally to the development of the UHTS used for several
nuclear receptors will be discussed.
Generic testing procedure for automated analyti-
cal chemistry workstations
Craig Bender, Searle R&D, Skokie, IL, USA
Automation of liquid handling for high-through-
put screening in 1536-well microplates with the
Robbins Hydra and automated plate positioning
system
David W. Batey and Jim Stanchfield, Robbins Scientific,
Sunnyvale, CA, USA
Distribution of compounds and dispensing of reagents
used in high-throughput screening assays are readily
performed with Hydra microdispensers. The 96 (or
384) glass syringes of the Hydra are held in a fixed
array positioned at the centre of each well in a standard
microplate. Precision mechanical components allow an
accuracy of+1% for dispensing I.tl with a coefficient of
variation of less than or equal to 3% across the syringe
array. With syringes available in sizes ranging from
1001al to ml, the Hydra is well suited for transfer of
bulk reagents as well as distribution of compounds in
submicrolitre volumes down to 100nl. When equipped
with the newly developed automated plate positioner, the
Hydra-96 and Hydra-384 are ideally suited for high-
throughput, repetitive dispensing procedures. All plate
and liquid handling functions can be controlled through
user-defined parameters within the included software or
through simple ASCII commands when used in an
integrated system. The stage can accommodate a combi-
nation of two plates of various well densities with a third
location dedicated as a wash reservoir that is filled and
emptied by peristaltic pumps. Settings for the positioning
of the plates during dispense/aspirate operations can be
adjusted in increments of 5 tm. This level of positional
accuracy allows consistent and reproducible access into
current 1536-well microplates as well as future high-
density formats. For reformatting operations, any combi-
nation of 96- (Hydra-96 only), 384- and 1536-well
microplates can be placed in the two plate positions
and re-arrayed through software protocols defined by
the user. Fluorescence signal was obtained for reactions
assembled and distributed into all wells of 1536-well
plates. By following recommended wash protocols for
the glass syringes, the results indicated no carryover
contamination between samples or reagents. Reaction
components included compounds stored in 100% DMSO
as well as aqueous reagents. Process time for reaction
assembly in 1536-well plates will be presented. The
Hydra-96 and Hydra-384 microdispensers, equipped with
the automated plate positioner stage and software make
up a complete high-throughput system for accurate,
precise dispensing into today’s high-density microplates.
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